[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 98 of about 98
1. Kim CW, Oh SJ, Rho YS, Cho SJ, Koh ES: A case of dysplastic nevus of the external auditory canal presenting with conductive hearing loss. Yonsei Med J; 2009 Dec 31;50(6):845-7
Genetic Alliance. consumer health - Nevus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A nevus which is a benign melanocytic neoplasm rarely occurs within the external auditory canal (EAC).
  • The mass showed clinically characteristic findings of a melanocytic nevus.

  • Genetic Alliance. consumer health - Conductive Hearing Loss.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 2001 Jul;137(7):917-20 [11453811.001]
  • [Cites] Ear Nose Throat J. 2003 Jan;82(1):38-41 [12610902.001]
  • [Cites] Arch Dermatol. 2003 Mar;139(3):282-8 [12622618.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2233-40 [14657431.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Jul;135(1):124-8 [16815196.001]
  • [Cites] Ear Nose Throat J. 1998 Jun;77(6):448 [9674315.001]
  • [Cites] J Cutan Pathol. 2005 Jul;32(6):405-12 [15953373.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S4-20 [16446715.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Mar;263(3):253-5 [16012861.001]
  • [Cites] J Otolaryngol. 1988 Aug;17(5):241-3 [3216448.001]
  • (PMID = 20046428.001).
  • [ISSN] 1976-2437
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2796414
  • [Keywords] NOTNLM ; External auditory canal / conductive hearing loss / dysplastic nevus / intradermal nevus
  •  go-up   go-down


2. Keijser S, Missotten GS, Bonfrer JM, de Wolff-Rouendaal D, Jager MJ, de Keizer RJ: Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions. Br J Ophthalmol; 2006 Feb;90(2):213-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions.
  • [MeSH-major] Antigens, Neoplasm / analysis. Conjunctival Diseases / diagnosis. S100 Proteins / analysis
  • [MeSH-minor] Biomarkers / analysis. Carcinoembryonic Antigen / analysis. Cell Cycle Proteins / analysis. Conjunctival Neoplasms / diagnosis. Conjunctival Neoplasms / immunology. Diagnosis, Differential. Humans. Immunohistochemistry / methods. MART-1 Antigen. Melanoma / diagnosis. Melanoma / immunology. Melanosis / diagnosis. Melanosis / immunology. Neoplasm Proteins / analysis. Nerve Growth Factors / analysis. Nevus / diagnosis. Nevus / immunology. S100 Calcium Binding Protein beta Subunit. Uveal Neoplasms / diagnosis. Uveal Neoplasms / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2000 Aug;10(4):350-4 [10985669.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Jan;46(1):75-82 [15623757.001]
  • [Cites] Trans Am Ophthalmol Soc. 2000;98:471-92 [11190037.001]
  • [Cites] Histopathology. 2001 Oct;39(4):426-31 [11683945.001]
  • [Cites] Am J Clin Oncol. 2002 Jun;25(3):248-55 [12040282.001]
  • [Cites] Arch Ophthalmol. 2002 Dec;120(12):1625-9 [12470134.001]
  • [Cites] Mod Pathol. 2003 May;16(5):505-11 [12748257.001]
  • [Cites] Arch Ophthalmol. 2003 Aug;121(8):1117-9 [12912688.001]
  • [Cites] Arch Ophthalmol. 1976 Mar;94(3):414-6 [1267924.001]
  • [Cites] Br J Cancer. 1989 Feb;59(2):261-7 [2649132.001]
  • [Cites] Ophthalmology. 1991 Apr;98(4):453-8 [1711186.001]
  • [Cites] Klin Monbl Augenheilkd. 1991 Sep;199(3):187-91 [1753671.001]
  • [Cites] Acta Ophthalmol (Copenh). 1992 Jun;70(3):289-96 [1636385.001]
  • [Cites] Ophthalmology. 1993 Feb;100(2):208-15 [8437829.001]
  • [Cites] Br J Ophthalmol. 1994 Apr;78(4):252-9 [8199108.001]
  • [Cites] Trends Biochem Sci. 1996 Apr;21(4):134-40 [8701470.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1996 Sep;234(9):569-72 [8880155.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):331-7 [9018119.001]
  • [Cites] J Cutan Pathol. 1997 Feb;24(2):76-80 [9162739.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):20283-90 [9242709.001]
  • [Cites] Br J Dermatol. 1997 Jul;137(1):39-43 [9274623.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):464-9 [9291441.001]
  • [Cites] Eur J Ophthalmol. 1998 Jan-Mar;8(1):4-7 [9590587.001]
  • [Cites] Klin Monbl Augenheilkd. 1998 Oct;213(4):230-7 [9848068.001]
  • [Cites] Biochim Biophys Acta. 1998 Dec 10;1448(2):290-7 [9920419.001]
  • [Cites] Br J Dermatol. 1999 Jun;140(6):1065-71 [10354072.001]
  • [Cites] Arch Ophthalmol. 2000 Nov;118(11):1497-507 [11074806.001]
  • (PMID = 16424536.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Carcinoembryonic Antigen; 0 / Cell Cycle Proteins; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / Nerve Growth Factors; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / S100A1 protein; 0 / S100B protein, human; 105504-00-5 / S100A6 protein, human
  • [Other-IDs] NLM/ PMC1860182
  •  go-up   go-down


3. Hussein MR, Elsers DA, Fadel SA, Omar AE: Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. J Clin Pathol; 2006 Mar;59(3):316-24
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.
  • We hypothesise that the transition from normal skin to benign naevi (BN) to melanocytic dysplastic naevi (MDN) to radial growth phase cutaneous malignant melanoma (RGP-CMM) to vertical growth phase cutaneous malignant melanoma (VGP-CMM) is associated with alterations in TIL.
  • This study attempted to test this hypothesis and to characterise TIL in the melanocytic skin lesions.
  • [MeSH-minor] Analysis of Variance. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Antigens, CD45 / analysis. Case-Control Studies. Disease Progression. Humans. Immunohistochemistry / methods. Immunophenotyping. Lymphocyte Count. Neoplasm Staging. Nevus / immunology. Nevus / pathology. T-Lymphocytes, Cytotoxic / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1990 Feb;125(2):200-5 [1689143.001]
  • [Cites] No To Shinkei. 1987 Apr;39(4):339-45 [2439110.001]
  • [Cites] Am J Dermatopathol. 1991 Apr;13(2):130-6 [1709340.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):313-9 [1741810.001]
  • [Cites] J Invest Dermatol. 1991 Aug;97(2):197-202 [1712819.001]
  • [Cites] J Invest Dermatol. 1991 Sep;97(3):425-9 [1831465.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):943-7 [1931621.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):420-5 [1495948.001]
  • [Cites] Jpn J Clin Oncol. 1992 Aug;22(4):256-63 [1331571.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2131-9 [7512443.001]
  • [Cites] Cancer Immunol Immunother. 1994 May;38(5):299-303 [8162611.001]
  • [Cites] Cancer Immunol Immunother. 1994 Sep;39(3):172-8 [7923247.001]
  • [Cites] J Immunol. 1995 Jan 15;154(2):772-9 [7814883.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2219-23 [7892250.001]
  • [Cites] Curr Top Microbiol Immunol. 1995;198:131-43 [7774278.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):765-72 [7790109.001]
  • [Cites] Eur J Immunol. 1995 Jun;25(6):1765-9 [7615005.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1343-8 [7543520.001]
  • [Cites] Br Med Bull. 1995 Jul;51(3):548-69 [7552081.001]
  • [Cites] J Interferon Cytokine Res. 1995 Aug;15(8):739-46 [8528947.001]
  • [Cites] Lancet. 1995 Nov 25;346(8987):1399-400 [7475823.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 20;87(24):1853-61 [7494229.001]
  • [Cites] Cancer Immunol Immunother. 1995 Nov;41(5):317-24 [8536278.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1303-10 [8608507.001]
  • [Cites] Clin Dermatol. 1995 Nov-Dec;13(6):551-7 [8882766.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6):688-92 [8970588.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6):693-702 [8970589.001]
  • [Cites] J Immunol. 1997 Jul 1;159(1):303-8 [9200467.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):52-5 [10658910.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):409-17 [10666369.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1484-91 [10717634.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1654-62 [10749136.001]
  • [Cites] Curr Opin Immunol. 2000 Jun;12(3):336-41 [10781407.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1875-81 [10815910.001]
  • [Cites] Acta Derm Venereol Suppl (Stockh). 2000;209:5-25 [10884941.001]
  • [Cites] J Immunother. 2000 Sep-Oct;23(5):557-69 [11001549.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):143-54 [11900990.001]
  • [Cites] Mol Carcinog. 2002 May;34(1):35-44 [12112321.001]
  • [Cites] Vet Pathol. 2002 Jul;39(4):445-51 [12126147.001]
  • [Cites] Presse Med. 2003 Jan 11;32(1):33-8 [12610395.001]
  • [Cites] Melanoma Res. 2003 Jun;13(3):263-9 [12777981.001]
  • [Cites] Arch Dermatol. 2003 Jun;139(6):816-7 [12810525.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1893-904 [2593166.001]
  • [Cites] Acta Neuropathol. 1989;79(2):211-6 [2596270.001]
  • [Cites] J Immunother. 1997 Nov;20(6):488-95 [9409455.001]
  • [Cites] Gene Ther. 1997 Oct;4(10):1061-8 [9415312.001]
  • [Cites] Int J Cancer. 1998 Jan 30;75(3):384-90 [9455798.001]
  • [Cites] Adv Immunol. 1999;72:209-53 [10361577.001]
  • [Cites] Cancer Lett. 1999 May 3;139(1):33-41 [10408906.001]
  • [Cites] Head Neck. 2004 Dec;26(12):1053-7 [15515159.001]
  • [Cites] Ned Tijdschr Geneeskd. 2004 Nov 13;148(46):2261-7 [15584540.001]
  • [Cites] Br J Dermatol. 2004 Dec;151(6):1213-8 [15606517.001]
  • [Cites] Mycopathologia. 2005 Feb;159(2):205-7 [15770444.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):983-8 [15467428.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):57-9 [15662123.001]
  • [Cites] Cancer Biol Ther. 2005 May;4(5):501-5 [15917653.001]
  • [Cites] Cancer Sci. 2003 Nov;94(11):1003-9 [14611679.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jun;128(6):686-8 [15163228.001]
  • [Cites] J Clin Pathol. 2004 Aug;57(8):797-801 [15280398.001]
  • [Cites] J Cutan Pathol. 2004 Nov;31(10):643-51 [15491323.001]
  • [Cites] Trans Ophthalmol Soc U K. 1977 Sep;97(3):394-401 [273996.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2749-53 [6342758.001]
  • [Cites] Wien Klin Wochenschr. 1986 Oct 24;98(20):673-8 [3788185.001]
  • [Cites] Nouv Rev Fr Hematol. 1990;32(1):9-11 [2349086.001]
  • (PMID = 16505286.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Biomarkers, Tumor; EC 3.1.3.48 / Antigens, CD45
  • [Other-IDs] NLM/ PMC1860334
  •  go-up   go-down


Advertisement
4. Florell SR, Bowen AR, Hanks AN, Murphy KJ, Grossman D: Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J Cutan Pathol; 2005 Jan;32(1):45-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi.
  • The apoptosis inhibitor survivin is expressed in melanoma and non-melanoma skin cancers and benign keratinocytic lesions.
  • Its expression has not been studied in melanocytic nevi.
  • OBJECTIVE: We determined the expression pattern of survivin in benign melanocytic nevi in comparison to markers of proliferation and apoptosis.
  • METHODS: Six cases of each of the following melanocytic nevi were retrieved from a dermatopathology archive: compound dysplastic nevus, intradermal nevus, compound nevus, neurotized intradermal nevus, and Spitz nevus.
  • Compound melanocytic lesions expressed survivin in both epidermal and dermal compartments.
  • CONCLUSIONS: Survivin is consistently expressed in benign melanocytic lesions, while apoptotic cells are rarely identified, suggesting the dysregulation of apoptotic pathways with the accumulation of cells in these neoplasms.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Dermatol. 1979 Mar;4(1):49-58 [445877.001]
  • [Cites] Am J Dermatopathol. 1993 Aug;15(4):311-4 [8105711.001]
  • [Cites] Am J Dermatopathol. 1993 Oct;15(5):441-5 [7902020.001]
  • [Cites] J Cutan Pathol. 1994 Oct;21(5):393-7 [7868749.001]
  • [Cites] Am J Dermatopathol. 1995 Feb;17(1):7-11 [7695015.001]
  • [Cites] J Am Acad Dermatol. 1995 Jun;32(6):964-7 [7751466.001]
  • [Cites] Arch Dermatol. 1995 Aug;131(8):915-8 [7632063.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] J Cutan Pathol. 1999 Feb;26(2):72-7 [10082396.001]
  • [Cites] J Invest Dermatol. 1999 Jul;113(1):111-6 [10417628.001]
  • [Cites] Lab Invest. 1999 Sep;79(9):1121-6 [10496530.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2941-53 [10561374.001]
  • [Cites] Nat Genet. 1999 Dec;23(4):387-8 [10581018.001]
  • [Cites] Nat Cell Biol. 1999 Dec;1(8):461-6 [10587640.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1076-81 [10594755.001]
  • [Cites] J Invest Dermatol. 2000 Aug;115(2):286-91 [10951248.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1415-30 [11073801.001]
  • [Cites] Blood. 2000 Dec 1;96(12):4002-3 [11186274.001]
  • [Cites] Am J Dermatopathol. 2000 Dec;22(6):489-95 [11190439.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):635-40 [11149963.001]
  • [Cites] J Invest Dermatol. 2002 Feb;118(2):386-7 [11841561.001]
  • [Cites] J Invest Dermatol. 2003 Jan;120(1):48-55 [12535197.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2683-92 [12855648.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1765-70 [14578177.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8568-80 [14634619.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8581-9 [14634620.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8590-607 [14634621.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):39-48 [14712209.001]
  • [Cites] Am J Dermatopathol. 2004 Jun;26(3):177-81 [15166502.001]
  • [Cites] Br J Cancer. 1972 Aug;26(4):239-57 [4561027.001]
  • [Cites] Cancer Res. 1976 Apr;36(4):1422-7 [816464.001]
  • (PMID = 15660660.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR050102-02; United States / NIAMS NIH HHS / AR / K08 AR048618; United States / NCRR NIH HHS / RR / K23RR17525; United States / NCRR NIH HHS / RR / K23 RR017525; United States / NIAMS NIH HHS / AR / R01 AR050102; United States / NIAMS NIH HHS / AR / R01 AR050102-02; United States / NIAMS NIH HHS / AR / KO8AR48618
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS44268; NLM/ PMC2292117
  •  go-up   go-down


5. Nino M, Brunetti B, Delfino S, Brunetti B, Panariello L, Russo D: Spitz nevus: follow-up study of 8 cases of childhood starburst type and proposal for management. Dermatology; 2009;218(1):48-51
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spitz nevus is an uncommon, benign melanocytic neoplasm that shares many clinical and histological features with melanoma.

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Spitz nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18832809.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Goodson AG, Florell SR, Boucher KM, Grossman D: Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. J Am Acad Dermatol; 2010 Apr;62(4):591-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi.
  • Of 61 benign nevus biopsy sites examined, clinical recurrence was observed in two (3.3%).
  • CONCLUSION: In this cohort, rates of clinical recurrence after biopsy of DN and benign nevi were extremely low.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • [Cites] Arch Dermatol. 2003 Oct;139(10):1374-5 [14568850.001]
  • [Cites] Arch Dermatol. 2003 Mar;139(3):282-8 [12622618.001]
  • [Cites] Arch Dermatol. 2003 Dec;139(12):1620-4; discussion 1624 [14676081.001]
  • [Cites] J Cutan Pathol. 2004 Sep;31(8):523-30 [15268706.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1121-31 [15509670.001]
  • [Cites] Arch Dermatol. 1975 Dec;111(12):1588-90 [1200664.001]
  • [Cites] J Am Acad Dermatol. 1987 Sep;17(3):459-68 [3655025.001]
  • [Cites] Australas J Dermatol. 1990;31(2):77-80 [2095738.001]
  • [Cites] JAMA. 1992 Sep 9;268(10):1314-9 [1507379.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1605-11 [8664138.001]
  • [Cites] JAMA. 1997 May 14;277(18):1439-44 [9145715.001]
  • [Cites] Med J Aust. 1997 Aug 18;167(4):191-4 [9293264.001]
  • [Cites] Dermatol Surg. 2005 Sep;31(9 Pt 1):1112-5 [16164859.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6):467-75 [18083370.001]
  • [Cites] J Am Acad Dermatol. 2008 Nov;59(5):814-21 [19119097.001]
  • [Cites] South Med J. 2009 Jan;102(1):45-8 [19077745.001]
  • [Cites] Cancer Biol Ther. 2008 Nov;7(11):1706-11 [18836285.001]
  • [Cites] Dermatol Surg. 2000 Jul;26(7):662-6 [10886275.001]
  • [Cites] Hautarzt. 2000 Aug;51(8):575-80 [10997312.001]
  • [Cites] J Pathol. 2002 Apr;196(4):459-66 [11920743.001]
  • [Cites] Dermatol Surg. 2003 Mar;29(3):227-9 [12614413.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2233-40 [14657431.001]
  • (PMID = 20018406.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR050102-05; United States / NIAMS NIH HHS / AR / R01 AR050102; United States / NIAMS NIH HHS / AR / R01 AR050102-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS204974; NLM/ PMC2886801
  • [Keywords] NOTNLM ; biopsy / dysplastic / nevi / recurrence
  •  go-up   go-down


7. Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL: Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Mod Pathol; 2008 Sep;21(9):1121-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
  • We re-evaluated the patterns of HMB45 staining across the 480-core 'SPORE melanoma progression array' containing lesions representing the spectrum of melanocytic lesions ranging from thin nevus to visceral metastasis using the fluorescence-based staining technique and automated quantitative analysis (AQUA) of the obtained digital images.
  • The odds ratio associated with a sample being a nevus was 2.24 (95% CI: 1.87-2.69, P<0.0001) for each 0.1 unit increase of the ln(nuclear/non-nuclear AQUA score ratio) to yield an ROC curve with 0.93 units of area and a simultaneously maximized sensitivity of 0.92 and specificity of 0.80 for distinguishing benign nevi from malignant melanomas.
  • On the basis of this preliminary study, we propose that the ratio of nuclear to non-nuclear HMB45 staining may be useful for diagnostic challenges in melanocytic lesions.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):914-6 [16900128.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21198-208 [16682408.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1175-80 [17667539.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):657-62 [11257096.001]
  • [Cites] J Cell Biol. 2001 Feb 19;152(4):809-24 [11266471.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10698-703 [11526213.001]
  • [Cites] Mol Biol Cell. 2001 Nov;12(11):3451-64 [11694580.001]
  • [Cites] Pathology. 2002 Feb;34(1):6-12 [11902448.001]
  • [Cites] Arch Dermatol. 2002 May;138(5):625-8 [12020223.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Int J Surg Pathol. 2003 Jan;11(1):11-5 [12598911.001]
  • [Cites] Am J Pathol. 1986 May;123(2):195-203 [3518473.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):680-4 [2473661.001]
  • [Cites] Am J Surg Pathol. 1990 Aug;14(8):748-51 [2378395.001]
  • [Cites] J Cutan Pathol. 1991 Aug;18(4):261-3 [1939785.001]
  • [Cites] J Invest Dermatol. 1993 Mar;100(3):313S-317S [8440911.001]
  • [Cites] Semin Diagn Pathol. 1993 Feb;10(1):76-91 [8506418.001]
  • [Cites] Am J Dermatopathol. 1995 Dec;17(6):542-6 [8599465.001]
  • [Cites] J Cutan Pathol. 1995 Dec;22(6):502-17 [8835170.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3223-9 [9242453.001]
  • [Cites] J Cutan Pathol. 1997 Oct;24(9):580-1 [9404857.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):976-82 [9706977.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):150-60 [10102344.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3937-41 [15867394.001]
  • [Cites] J Cutan Pathol. 2006 Mar;33(3):207-15 [16466507.001]
  • [Cites] Pigment Cell Res. 2006 Jun;19(3):250-2; author reply 253-7 [16704461.001]
  • [Cites] J Cutan Pathol. 2007 Jul;34(7):576-80 [17576338.001]
  • (PMID = 18552823.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA121974-02; United States / NCI NIH HHS / CA / R01 CA114277; United States / NCI NIH HHS / CA / P50 CA121974-02; United States / NCI NIH HHS / CA / R01 CA114277-02; United States / NCI NIH HHS / CA / CA114277-02; United States / NCI NIH HHS / CA / R0-1 CA01142777; United States / NCI NIH HHS / CA / P50 CA121974; United States / NCI NIH HHS / CA / 1P50 CA121974
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melanoma-Specific Antigens; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PMEL protein, human; 0 / Si protein, mouse; 0 / gp100 Melanoma Antigen
  • [Other-IDs] NLM/ NIHMS67484; NLM/ PMC2570478
  •  go-up   go-down


8. Berman DM, Wincovitch S, Garfield S, Romeo MJ: Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. J Clin Pathol; 2005 Nov;58(11):1206-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index.
  • BACKGROUND: Although nucleic acid derangements are the hallmark of melanocytic dysplasia, the gold standard for its diagnosis remains the microscopic evaluation of haematoxylin and eosin stained slides.
  • METHODS: Confocal laser scanning microscopy was performed on melanocytic lesions stained with acridine orange (AO), a fluorescent stain for DNA and RNA.
  • RESULTS: When applied to benign naevi, dysplastic naevi, and melanoma, a very strong significant association was seen between lower NAI and malignant potential (p < 0.0001).
  • Interestingly, the NAI for dysplastic naevi is between that of melanoma and most benign naevi, consistent with their intermediate biological behaviour and histological appearance.
  • CONCLUSION: By providing a quantitative measure for melanocytic neoplasia, the NAI may improve the diagnosis of melanocytic lesions and the selection of treatment.
  • [MeSH-major] DNA, Neoplasm / analysis. Dysplastic Nevus Syndrome / diagnosis. Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Image Processing, Computer-Assisted / methods. Melanocytes / pathology. Microscopy, Confocal / methods. Mitotic Index. Nevus, Pigmented / diagnosis. Nevus, Pigmented / genetics. Nevus, Pigmented / pathology. Paraffin Embedding. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1998 Nov;96(5):487-94 [9829812.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):419-26 [9816186.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Am J Dermatopathol. 2003 Jun;25(3):190-7 [12775980.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3081-6 [12789284.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):764-71 [12920220.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Oct;25(5):243-53 [14603721.001]
  • [Cites] Melanoma Res. 2003 Dec;13(6):581-6 [14646621.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):179-85 [14996086.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):342-8 [15009715.001]
  • [Cites] J Am Acad Dermatol. 2004 Jul;51(1 Suppl):S65-9 [15243517.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121 Suppl:S3-32 [15298148.001]
  • [Cites] Lancet. 1977 Apr 16;1(8016):864-5 [67377.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):732-8 [646394.001]
  • [Cites] Cancer Res. 1978 Jul;38(7):1893-8 [77721.001]
  • [Cites] Microsc Acta. 1981 Jan;84(1):37-42 [6163065.001]
  • [Cites] Cytometry. 1982 Jan;2(4):212-8 [6173180.001]
  • [Cites] Cytometry. 1982 Jul;3(1):28-35 [6180873.001]
  • [Cites] Am J Clin Pathol. 1985 Jun;83(6):722-5 [2408462.001]
  • [Cites] J Am Acad Dermatol. 1989 Oct;21(4 Pt 1):773-80 [2808793.001]
  • [Cites] J Cutan Pathol. 1993 Apr;20(2):121-5 [8320355.001]
  • [Cites] Kurume Med J. 1994;41(1):1-13 [7933912.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):528-31 [8666360.001]
  • [Cites] Cytometry. 1997 Feb 1;27(2):99-105 [9012376.001]
  • [Cites] Histochem Cell Biol. 1997 Apr;107(4):267-78 [9151109.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1370-7 [10717619.001]
  • (PMID = 16254113.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC1770753
  •  go-up   go-down


9. Datiashvili RO, Izadi K, Centurion SA, Lambert WC, Scarpidis U: Malignant melanocytic trichoblastoma. Ann Plast Surg; 2006 Feb;56(2):208-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanocytic trichoblastoma.
  • Trichoblastoma is an uncommon benign cutaneous neoplasm of the hair germ cell.
  • We are presenting a case report of a 47-year-old patient with malignant trichoblastoma containing melanin deposits and propose to define this variety of the tumor as a separate entity: malignant melanocytic trichoblastoma.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432335.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down


10. Mentzel T: [Uncommon variants of malignant melanocytic neoplasms]. Pathologe; 2007 Nov;28(6):445-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uncommon variants of malignant melanocytic neoplasms].
  • Benign and malignant melanocytic neoplasms are relatively frequent and show a broad morphological heterogeneity.
  • The latter include nevoid malignant melanoma, a form of malignant melanoma resembling benign melanocytic nevi, animal type malignant melanoma, an atypical melanocytic neoplasm with numerous melanophages and prominent melanosis resembling an atypical epithelioid blue naevus as well as regressive malignant melanoma, and representing a questionably distinct entity, balloon cell and signet-ring malignant melanomas, melanoma types with degenerative clear cell changes, as well as myxoid and osteogenic malignant melanomas that are characterized by unusual stromal changes.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846776.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Plótár V, Szentirmay Z, Orosz Z: [Reactivity of five different antibodies with benign and malignant melanocytic lesions]. Magy Onkol; 2008 Dec;52(4):363-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reactivity of five different antibodies with benign and malignant melanocytic lesions].
  • At the histological examination of an increasing number of melanocytic tumors there is a need to use various immunohistochemical methods.
  • We have tested five antibodies (S-100, HMB-45, Melan-A, MITF, PNL-2) on 34 benign and 34 malignant melanocytic tumors.
  • We have concluded that the histological diagnosis of melanocytic tumors is based on the detailed examination of traditional HE slides and the immunohistochemical methods only confirm or weaken our opinion.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Immunohistochemistry. Melanoma / chemistry. Neoplasm Proteins / analysis. Nevus / chemistry. Skin Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068464.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MITF protein, human; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins; 0 / S100 Proteins; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.10 / pectin lyase
  •  go-up   go-down


12. Tallon B, Cerroni L: Where pigmented pilomatricoma and melanocytic matricoma collide. Am J Dermatopathol; 2010 Dec;32(8):769-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Where pigmented pilomatricoma and melanocytic matricoma collide.
  • Pilomatricoma and matricoma are 2 benign epithelial tumours derived from the hair matrix.
  • The recently described melanocytic matricoma appears to be a similar tumor with numerous interspersed melanocytes.
  • Three cases of pilomatricoma with prominent melanocytic hyperplasia were detected, confirming this as a rare (11%) occurrence.
  • Comparison of these tumors with a further case of melanocytic matricoma led to a critical analysis of the relationship of pilomatricoma, matricoma, and melanocytic matricoma.
  • Although further comparison is required, we suggest that melanocytic matricoma may be simply a pigmented melanocytic variant of matricoma, in the same way as we accept pigmented pilomatricoma as a variant of pilomatricoma.
  • [MeSH-minor] Adolescent. Aged. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Cell Proliferation. Child. Diagnosis, Differential. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Predictive Value of Tests. Retrospective Studies. S100 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881831.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melan-A 51-73 peptide; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


13. Nasr MR, El-Zammar O: Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol; 2008 Apr;30(2):117-22
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
  • Differentiating malignant melanoma from benign melanocytic lesions can be challenging.
  • We undertook this study to evaluate the use of the immunohistochemical mitosis marker phospho-Histone H3 (pHH3) and the proliferation markers Ki-67 and survivin in separating malignant melanoma from benign nevi.
  • Sixty-six melanocytic lesions (18 malignant melanomas, 8 Spitz nevi, 20 dysplastic nevi, and 20 compound nevi) were stained with antibodies to pHH3, Ki-67, and survivin.
  • There was no cytoplasmic staining for survivin in any of the 66 melanocytic lesions and no nuclear staining in any of the benign ones.
  • In benign melanocytic lesions, the Ki-67 index was less than 5% (range 0%-4%) and staining was present close to the dermo-epidermal junction compared with an average index of 27% in melanomas (range 5%-50%) and a generally heterogeneous pattern of staining throughout the dermis. pHH3 and Ki-67 can be useful adjuncts to histopathology to separate malignant melanoma from benign nevi. pHH3 is especially useful to highlight mitoses and to rapidly assess the mitotic activity in melanocytic lesions.
  • [MeSH-major] Biomarkers, Tumor / analysis. Histones / analysis. Ki-67 Antigen / analysis. Melanoma / chemistry. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Nevus, Epithelioid and Spindle Cell / chemistry. Nevus, Pigmented / chemistry. Skin Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360113.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Histones; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


14. Jakobiec FA, Colby K, Bajart AM, Saragas SJ, Moulin A: Immunohistochemical studies of atypical conjunctival melanocytic nevi. Arch Ophthalmol; 2009 Aug;127(8):970-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical studies of atypical conjunctival melanocytic nevi.
  • OBJECTIVE: To evaluate with immunohistochemical methods 5 atypical melanocytic conjunctival lesions.
  • RESULTS: A unique granular cell nevus contained periodic acid-Schiff-positive, diastase-resistant granules and immunoreacted with monoclonal antibodies against S-100 protein and melanocytic-associated antigens MART-1 and HMB-45.
  • CONCLUSIONS: S100 and MART-1 reliably immunostained all nevocytic morphologic variants.
  • Ki-67 was the most valuable immunohistochemical adjunct to morphology for the diagnosis of these benign variant conjunctival nevi, because melanomas display a much higher proliferation index (>10% nuclear positivity among all cells counted) than the current nevi (approximately 1%).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Conjunctival Neoplasms / metabolism. Neoplasm Proteins / metabolism. Nevus, Blue / metabolism. Nevus, Pigmented / metabolism
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, Neoplasm / metabolism. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. MART-1 Antigen. Male. Melanoma-Specific Antigens. Middle Aged. Muramidase / metabolism. Retrospective Studies. S100 Proteins / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667333.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


15. Fröhlich E, Mack AF, Garbe C, Klessen C: Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas. Br J Dermatol; 2005 Dec;153(6):1159-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
  • BACKGROUND: Melanomas are heterogeneous tumours, and differentiation from other melanocytic lesions may cause problems.
  • It may be possible that the distribution and/or colocalization pattern of different markers in the lesions can enable a more accurate diagnosis of melanocytic tumours.
  • OBJECTIVES: To test this hypothesis, melanocytic naevi, primary melanomas and metastases were investigated.
  • RESULTS: Malignant melanomas tended to express more markers of malignancy compared with melanocytic naevi, and the differences were statistically significant for EGF and actin immunoreactivity: melanocytic naevi displayed clear EGF labelling more often (60% vs. 5%) and melanomas showed more intense actin labelling (70% vs. 0%).
  • Similar combinations were observed in melanocytic naevi and in melanomas.
  • CONCLUSIONS: Labelling with EGF may improve the differential diagnosis of melanocytic neoplasias.
  • Cells expressing multiple malignancy markers were also found in some melanocytic naevi; this may confirm the dormant potential of melanocytic naevi for melanoma development.
  • [MeSH-minor] Cell Movement. Cell Proliferation. Diagnosis, Differential. Epidermal Growth Factor / metabolism. Humans. Neoplasm Invasiveness. Neoplasm Proteins / metabolism. Neovascularization, Pathologic / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16307652.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


16. Chwirot BW, Kuźbicki Ł: Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma Res; 2007 Jun;17(3):139-45
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
  • In this study, we investigated whether the COX-2 expression level might be a useful immunohistochemical marker for distinguishing cutaneous melanomas from benign melanocytic lesions.
  • In conclusion, COX-2 is the first immunohistochemical marker that allows the distinguishing of early melanomas from benign melanocytic lesions with both high sensitivity and specificity.
  • [MeSH-minor] Algorithms. Diagnosis, Differential. Humans. Melanocytes / enzymology. Melanocytes / pathology. Neoplasm Staging. Predictive Value of Tests. ROC Curve. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505259.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


17. Schwartz RA, Rothenberg J: Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease. J Cutan Pathol; 2010 Dec;37(12):1251-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease.
  • It is rare to find it in association with a benign melanocytic nevus.
  • We describe a patient with metastatic adenocarcinoma of breast within a benign melanocytic nevus and delineate this occurrence within the context of reviewing cutaneous breast metastatic disease.
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 20002237.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


18. Wu J, Rosenbaum E, Begum S, Westra WH: Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol; 2007 Dec;29(6):534-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
  • A description of mutation distribution in nevi could provide insight into the significance of this event in melanocytic tumorigenesis.
  • [MeSH-minor] Adolescent. Adult. Aged. Anus Neoplasms / genetics. Anus Neoplasms / pathology. Anus Neoplasms / surgery. Back / pathology. Child. DNA Mutational Analysis. DNA, Neoplasm / analysis. Extremities / pathology. Female. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Male. Microdissection. Middle Aged. Urogenital Neoplasms / genetics. Urogenital Neoplasms / pathology. Urogenital Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032947.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


19. Hussein MR, Elsers DA, Fadel SA, Omar AE: Clinicopathological features of melanocytic skin lesions in Egypt. Eur J Cancer Prev; 2006 Feb;15(1):64-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of melanocytic skin lesions in Egypt.
  • Although melanocytic skin lesions have been recognized since antiquity, their literature was limited to Caucasians.
  • To define these features, diagnostic records of the melanocytic skin lesions received at the Pathology Department, Assuit University Hospitals (1989-2004) were reviewed.
  • The lesions examined included 12 benign naevi (BN), 10 dysplastic naevi (DN), and 21 cutaneous malignant melanomas (CMMs).
  • In Egypt, CMM is the third most common cutaneous neoplasm following squamous and basal cell carcinomas.
  • This is the first study that reports the clinicopathologic features of melanocytic skin lesions in Egypt.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374232.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Ahmadi N, Davison SP, Kauffman CL: Melanocytic nevi with Spitz differentiation: diagnosis and management. Laryngoscope; 2010 Dec;120(12):2385-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanocytic nevi with Spitz differentiation: diagnosis and management.
  • OBJECTIVES: Melanocytic proliferations with Spitz differentiation present a difficult clinicopathologic dilemma, as their spectrum ranges from benign to malignant.
  • Their histopathologic differentiation can be challenging, and cases of Spitzoid melanoma initially diagnosed as benign Spitz nevi are reported in the literature.
  • The goal of this article is to discuss the diagnostic tools (including comparative genomic hybridization), which may be helpful in differentiating benign Spitz nevi from malignant melanoma with Spitzoid features, and to propose an appropriate management strategy for each entity.
  • CONCLUSIONS: Otolaryngologists, plastic surgeons and dermatopathologists will encounter patients who have melanocytic lesions with Spitz differentiation at some point in their career.
  • [MeSH-major] Neoplasm Staging / methods. Nevus, Epithelioid and Spindle Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21072755.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB: BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res; 2006 Aug;16(4):267-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF and NRAS mutations in melanoma and melanocytic nevi.
  • In this report, we investigated BRAF/NRAS mutations in samples from a case-control study of melanoma and a series of benign melanocytic nevi.
  • Our data support the evidence that the mitogen-activated protein kinase pathway is upregulated in a large percentage of melanocytic lesions, but these mutations are not sufficient for malignant transformation.
  • We suggest that BRAF mutations contribute to benign melanocytic hyperplasia, but are likely to contribute to invasive melanoma only in conjunction with other mutations.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845322.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102096-03; United States / NCI NIH HHS / CA / K07 CA102096-03; United States / NCI NIH HHS / CA / CA112243-03; United States / NCI NIH HHS / CA / K07 CA102096; United States / NHGRI NIH HHS / HG / T32 HG 00040; United States / NCI NIH HHS / CA / U01 CA83180; United States / NCI NIH HHS / CA / R01 CA112243-03; United States / NCI NIH HHS / CA / R01 CA112243
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


22. Bauer J, Bastian BC: [DNA copy number changes in the diagnosis of melanocytic tumors]. Pathologe; 2007 Nov;28(6):464-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [DNA copy number changes in the diagnosis of melanocytic tumors].
  • CGH analysis has revealed that melanomas differ from melanocytic nevi in the presence of frequent chromosomal aberrations.
  • CGH analysis of benign melanocytic tumors typically shows no clonally expanded chromosomal aberrations, while in the vast majority of melanomas gains and losses of particular chromosomes are found.
  • These marked differences between the aberration patterns of melanomas and melanocytic nevi can be exploited during differential diagnosis of melanocytic tumors in which histopathologic assessment yields equivocal results.
  • A study checking for correlations between the chromosomal alterations in melanocytic tumors not classified at diagnosis and the course of illness in patients is currently under way.
  • [MeSH-major] Chromosome Aberrations. DNA, Neoplasm / genetics. Melanoma / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882420.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


23. Pisacane AM, Risio M: VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Melanoma Res; 2005 Feb;15(1):39-43
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas.
  • In order to determine their possible role in the acquisition of metastatic potential throughout melanocytic tumour progression, VEGF and VEGFR-2 immunohistochemical expression were evaluated in 36 human melanocytic tumours of the skin (24 malignant melanomas and 12 common naevi).
  • Taken together, these data indicate that VEGF production is a common event in benign melanocytic tumours, whereas VEGFR-2 expression, co-localized in the cytoplasmic and nuclear membrane, is associated with progression towards invasive melanoma.
  • [MeSH-minor] Cell Nucleus / metabolism. Cell Nucleus / pathology. Cytoplasm / metabolism. Cytoplasm / pathology. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714119.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


24. Vetter CS, Müller-Blech K, Schrama D, Bröcker EB, Becker JC: Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch Dermatol Res; 2005 Jul;297(1):26-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions.
  • In the present study, we compared the expression of survivin in melanoma and benign melanocytic lesions such as junctional, compound, dermal, congenital, blue and spitz nevi.
  • Our data demonstrate that although survivin is expressed in a large number of benign nevi, the balance between its cytoplasmic and nuclear expression was immensely heterogeneous between lesions with suspected different developmental origins.
  • [MeSH-major] Cell Nucleus / chemistry. Cytoplasm / chemistry. Melanoma / chemistry. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Nevus / chemistry. Skin Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906050.001).
  • [ISSN] 0340-3696
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


25. Karim RZ, Li W, Sanki A, Colman MH, Yang YH, Thompson JF, Scolyer RA: Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors. Int J Surg Pathol; 2009 Oct;17(5):361-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
  • The immunohistochemical expression of cell cycle proteins p16, cyclin D1, and pRb was assessed in 112 benign and malignant melanocytic tumors and correlated with tumor progression, prognosis, and outcome.
  • Comparing benign and malignant tumors, there were significant differences in the median score for all 3 proteins, with decreased p16 (P = .000001), increased cyclin D1 (P = .01), and increased pRb in melanomas (P = .01).
  • There was a progressive loss of expression of p16 with progression from benign naevi to primary melanomas and to metastases. p16 was significantly decreased in primary tumors from melanoma patients who developed recurrent disease (P = .0000013).
  • Cyclin D1 and pRb showed a progressive increase in expression from benign to malignant tumors but with relative decreases in the more advanced tumors (thick primaries and metastatic melanomas).
  • Alterations in cell cycle proteins involved in G1/S transition are implicated in melanocytic tumor progression and have a potential role in diagnosis and prognostication.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Disease Progression. Female. Humans. Immunoenzyme Techniques. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Melanocytes / metabolism. Melanocytes / pathology. Middle Aged. Neoplasm Recurrence, Local. Prognosis


26. Singh RS, Diwan AH, Zhang PS, Prieto VG: Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions. J Cutan Pathol; 2007 Mar;34(3):220-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
  • BACKGROUND: Although various studies have stressed the role of phosphatase and tensin homologue deleted on chromosome 10 (PTEN)-PI3K-AKT pathway in the progression of melanocytic lesions, little is known about the expression pattern of PI3K in these lesions.
  • OBJECTIVE: To investigate the expression pattern of PI3K in benign and dysplastic nevi, primary melanomas, and metastatic melanomas and the role of PTEN and PI3K in melanocytic tumor progression.
  • METHODS: Tissue microarrays were constructed using formalin-fixed, paraffin-embedded archival tissue blocks from 89 melanocytic lesions: 17 benign nevi, 18 dysplastic nevi, 23 primary melanomas, and 31 metastatic melanomas.
  • RESULTS: Both benign and dysplastic nevi showed strong cytoplasmic staining with PTEN, which was subsequently less in melanomas and completely lost in the metastatic lesions.
  • Eleven of 17 (64%) benign nevi, seven of 10 (70%) dysplastic nevi, four of 23 (17%) primaries, and one of 31 (3%) visceral or lymph node metastasis showed strong positivity.
  • Loss of PTEN expression from benign and dysplastic nevi to melanoma was statistically significant (p=0.001).
  • Although few cells showed reactivity for phosphoinositide 3-kinase (PI3 kinase)-p85 subunit, strong positivity was not detected in the cytoplasm of benign, malignant, or metastatic lesions, except for a single visceral metastasis.
  • There was no statistical difference in PI3 kinase expression in benign and malignant melanocytic lesions (p=0.2).
  • CONCLUSION: PI3K is not overexpressed in melanocytic lesions.
  • [MeSH-minor] Humans. Immunohistochemistry. Neoplasm Metastasis. PTEN Phosphohydrolase / metabolism. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302605.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


27. Furusato E, Hidayat AA, Man YG, Auerbach A, Furusato B, Rushing EJ: WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases. Arch Ophthalmol; 2009 Aug;127(8):964-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
  • OBJECTIVE: Recent studies indicate that WT1 and Bcl2 protein are detected in melanocytic lesions of the skin.
  • We examined, for the first time, WT1 and Bcl2 expression in a variety of conjunctival melanocytic lesions to evaluate their diagnostic utility compared with other melanocytic markers.
  • METHODS: Protein expression and localization of WT1 and Bcl2 were studied by means of immunolabeling and semiquantification in 123 conjunctival melanocytic lesions (71 benign nevi, 21 atypical nevi, 11 primary acquired melanosis, and 20 malignant melanomas).
  • WT1 and HMB45 frequently showed diffuse and strong staining in atypical nevi, primary acquired melanosis with atypia, and malignant melanomas compared with benign lesions.
  • CONCLUSIONS: Bcl2 is a highly sensitive immunohistochemical marker for melanocytic tumors of the conjunctiva; HMB45 and WT1 staining distinguishes benign from malignant lesions.
  • CLINICAL RELEVANCE: Our results show that HMB45 and WT1 immunolabeling is helpful in the evaluation of conjunctival melanocytic lesions.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Conjunctival Neoplasms / metabolism. Melanoma / metabolism. Neoplasm Proteins / metabolism. Nevus, Pigmented / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. Child. Child, Preschool. Conjunctival Diseases / metabolism. Dysplastic Nevus Syndrome / metabolism. Dysplastic Nevus Syndrome / pathology. Female. Humans. Immunoenzyme Techniques. MART-1 Antigen. Male. Melanoma-Specific Antigens. Melanosis / metabolism. Melanosis / pathology. Middle Aged. S100 Proteins / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667332.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / S100 Proteins; 0 / WT1 Proteins
  •  go-up   go-down


28. Miteva M, Lazova R: Spitz nevus and atypical spitzoid neoplasm. Semin Cutan Med Surg; 2010 Sep;29(3):165-73
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for spitz nevus .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spitz nevus and atypical spitzoid neoplasm.
  • Spitz nevus (SN) and Spitzoid malignant melanoma (SMM) represent benign and malignant counterparts at both ends of the spectrum of Spitzoid lesions.
  • Atypical Spitzoid neoplasm (ASN) is a poorly defined and characterized category of melanocytic tumors with histologic features of both benign Spitz nevi and malignant melanomas.
  • Because this group encompasses both benign and malignant lesions, and perhaps also a separate category of melanocytic tumors that behave better than conventional melanomas, some of these neoplasms can metastasize and kill patients, whereas others have no metastatic potential, and yet others might only metastasize to regional lymph nodes.
  • At this time histologic examination remains the golden standard for diagnosing these melanocytic neoplasms.
  • We also review the most recent advances in immunohistochemical and molecular diagnostics as well as discuss the controversies and dilemma regarding whether to consider sentinel lymph node biopsy for diagnostically ambiguous melanocytic neoplasms.

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Spitz nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21051010.001).
  • [ISSN] 1558-0768
  • [Journal-full-title] Seminars in cutaneous medicine and surgery
  • [ISO-abbreviation] Semin Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


29. Miracco C, De Nisi MC, Arcuri F, Cosci E, Pacenti L, Toscano M, Lalinga AV, Biagioli M, Rubegni P, Vatti R, Maellaro E, Del Bello B, Massi D, Luzi P, Tosi P: Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours. Int J Oncol; 2006 Feb;28(2):345-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
  • Recent studies seem to confirm its active role in melanoma pathobiology; however, its expression has not yet been extensively studied in melanocytic tumours.
  • We evaluated MIF protein expression in 126 skin lesions, including benign and atypical nevi, melanoma and melanoma metastases.
  • Benign nevi were subdivided into nevocytic and Spitz/blue types; and melanomas into the radial, and vertical growth phase.
  • All samples expressed MIF mRNA but it was significantly lower in benign nevi vs atypical nevi, melanomas and metastases (p=0.001; p<0.0001; p=0.002, respectively).
  • Our study shows a widespread distribution of MIF among melanocytic tumours.
  • Whereas we observed a trend towards higher expression levels of mRNA in atypical and malignant tumours, MIF protein was highly expressed in all lesions, although limited to the cytoplasm in most benign nevi.
  • These observations suggest differences in MIF protein storage, subcellular location and properties in most benign nevi vs atypical and malignant tumours that should be confirmed by further investigation and correlation with clinical outcome.
  • [MeSH-minor] Cell Nucleus / metabolism. Cytoplasm / metabolism. Humans. Immunohistochemistry. Neoplasm Metastasis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391788.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Macrophage Migration-Inhibitory Factors; 0 / RNA, Messenger
  •  go-up   go-down


30. Cohn ML, Goncharuk VN, Diwan AH, Zhang PS, Shen SS, Prieto VG: Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms. J Cutan Pathol; 2005 Sep;32(8):533-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms.
  • Immunohistochemical studies were performed on tissue microarrays containing 19 benign melanocytic nevi (BN), 21 dysplastic nevi (DN), 23 primary malignant melanomas (MMs), and 31 metastatic melanomas (MMMs) using a polyclonal anti-claudin-1 antibody.
  • Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms.
  • [MeSH-minor] Blood Vessels / metabolism. Blood Vessels / pathology. Claudin-1. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Neoplasm Metastasis. Phenotype. Protein Array Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115050.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Membrane Proteins
  •  go-up   go-down


31. Indsto JO, Kumar S, Wang L, Crotty KA, Arbuckle SM, Mann GJ: Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions. J Cutan Pathol; 2007 Jun;34(6):448-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
  • Melanocytic lesions, including Spitz nevi (SN), common benign nevi (CBN) and cutaneous metastatic melanoma (CMM), were analyzed for activating mutations in NRAS, HRAS and BRAF oncogenes, which induce cellular proliferation via the MAP kinase pathway.
  • [MeSH-minor] Adolescent. Australia / epidemiology. Cell Line, Tumor. Child, Preschool. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Prevalence


32. King R, Googe PB, Page RN, Mihm MC Jr: Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ. Mod Pathol; 2005 Aug;18(8):1043-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ.
  • A single case of lentiginous melanocytic hyperplasia overlying a dermatofibroma has been reported, however, nevi and melanoma have to the best of our knowledge, not been previously reported.
  • We present 14 cases of melanocytic lesions associated with dermatofibromas.
  • Histologically, the melanocytic lesions included junctional, compound, and dermal nevi, and malignant melanoma in situ.
  • Immunohistochemically, the melanocytic lesions were S-100/ Mart-1+, FXIIIa-, and the dermatofibromas were S-100/Mart-1-, FXIIIa+.
  • Melanocytic neoplasia may appear in association with dermatofibromas.
  • The fibrohistiocytic proliferation may be misinterpreted as a spindle or pleomorphic melanocytic process.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Melanocytes / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm. Factor XIIIa / analysis. Female. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanoma / metabolism. Melanoma / pathology. Middle Aged. Neoplasm Proteins / analysis. Nevus / metabolism. Nevus / pathology. Proto-Oncogene Proteins c-kit / analysis. S100 Proteins / analysis

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803191.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / S100 Proteins; EC 2.3.2.13 / Factor XIIIa; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


33. Wong RP, Khosravi S, Martinka M, Li G: Myeloid leukemia-1 expression in benign and malignant melanocytic lesions. Oncol Rep; 2008 Apr;19(4):933-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid leukemia-1 expression in benign and malignant melanocytic lesions.
  • [MeSH-major] Dysplastic Nevus Syndrome / metabolism. Melanoma / chemistry. Neoplasm Proteins / analysis. Nevus / chemistry. Proto-Oncogene Proteins c-bcl-2 / analysis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357378.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


34. Gerami P, Barnhill RL, Beilfuss BA, LeBoit P, Schneider P, Guitart J: Superficial melanocytic neoplasms with pagetoid melanocytosis: a study of interobserver concordance and correlation with FISH. Am J Surg Pathol; 2010 Jun;34(6):816-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial melanocytic neoplasms with pagetoid melanocytosis: a study of interobserver concordance and correlation with FISH.
  • Pagetoid proliferation of single melanocytic cells or small nests of melanocytes may be seen in a variety of melanocytic neoplasms including pagetoid spitz nevi, de novo epithelioid melanocytic dysplasia, and melanoma.
  • In this study, we collected 24 cases of superficial melanocytic neoplasms with prominent pagetoid melanocytosis.
  • We allowed 3 experienced consultant dermatopathologists to independently evaluate these entities and score them from 1 to 4, with 1 being totally benign and 4 being melanoma.
  • None of the cases with a consensus diagnosis of benign were FISH positive.
  • There is considerable discordance in superficial melanocytic neoplasm with prominent pagetoid melanocytosis even among expert consultants.


35. Nazarian RM, Prieto VG, Elder DE, Duncan LM: Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol; 2010 Apr;37 Suppl 1:41-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
  • BACKGROUND: The elucidation of protein biomarkers that are differentially expressed in human melanocytic tumors during tumor progression may lead to the identification of therapeutic targets and novel diagnostic tests.
  • The specialized programs of research excellence (SPORE) in skin cancer developed a melanocytic tumor progression tissue microarray (TMA) to evaluate these candidate biomarkers.
  • METHODS: The TMA contains 480 cores of benign nevi, primary cutaneous melanoma and melanoma metastases.
  • CONCLUSIONS: Through a collaboration of the Skin SPOREs sponsored by the Organ Systems Branch of the National Cancer Institute (NCI), we identified a list of melanoma biomarkers of interest, developed a melanocytic tumor progression TMA and completed a coordinated analysis of these biomarkers.
  • This TMA has served as a powerful validation tool for newly identified and known melanoma biomarkers by revealing trends in expression during tumor progression and by confirming the heterogeneity of biomarker expression in cutaneous melanocytic tumors.
  • [MeSH-minor] Antigens, Neoplasm / metabolism. Cell Nucleus / metabolism. Disease Progression. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. MART-1 Antigen. Melanoma-Specific Antigens. Microphthalmia-Associated Transcription Factor / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20482674.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / MART-1 Antigen; 0 / MITF protein, human; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Microphthalmia-Associated Transcription Factor; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


36. Strauss RM, Elliott F, Affleck P, Boon AP, Newton-Bishop JA: A retrospective study addressed to understanding what predicts severe histological dysplasia/early melanoma in excised atypical melanocytic lesions. Br J Dermatol; 2007 Oct;157(4):758-64
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study addressed to understanding what predicts severe histological dysplasia/early melanoma in excised atypical melanocytic lesions.
  • BACKGROUND: Atypical naevi are common benign skin lesions but are also recognized both as precursors of and risk factors for melanoma.
  • Clinically, however, it may be difficult to distinguish these from benign atypical naevi with bland histology.
  • OBJECTIVES: To analyse the clinical characteristics of excised melanocytic lesions and to identify the predictors of severe histological atypia/melanoma in situ and invasive melanoma.
  • METHODS: The case notes of 434 patients who had melanocytic lesions removed at a pigmented lesion clinic were studied retrospectively.
  • CONCLUSIONS: These results confirm the difficulty of differentiating accurately between benign atypical naevi and borderline lesions or early melanoma in a clinical setting.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714559.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Zarineh A, Kozovska ME, Brown WG, Elder DE, Rabkin MS: Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus, a case report and review of the literature. J Cutan Pathol; 2008 Oct;35 Suppl 1:83-6
Genetic Alliance. consumer health - Nevus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus, a case report and review of the literature.
  • Smooth muscle hamartoma (SMH) is a rare benign congenital or acquired lesion sometimes associated with Becker's nevus (Becker's melanosis).
  • We report an unusual lesion with combined features of SMH and melanocytic nevus.
  • The melanocytic component strongly expressed melanoma antigen recognized by T-cells-1 (MART-1) and HMB-45.
  • Unlike a recently reported case of SMH combined with a melanocytic nevus and basal cell carcinoma, the current lesion did not occur in association with a Becker's nevus.
  • [MeSH-minor] Actins / metabolism. Antigens, Neoplasm / metabolism. Calmodulin-Binding Proteins / metabolism. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2008.
  • (PMID = 18544054.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Calmodulin-Binding Proteins; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


38. Kuźbicki L, Gajo B, Chwirot BW: Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions. Melanoma Res; 2006 Jun;16(3):235-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
  • The present study was aimed at examining levels of lysosome-associated membrane protein-1 in human melanomas and benign pigmented lesions to evaluate whether this protein might be considered a potential molecular marker of melanoma progression.
  • [MeSH-minor] Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Recurrence, Local / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16718270.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lysosomal-Associated Membrane Protein 1
  •  go-up   go-down


39. Bauer R, Wild PJ, Meyer S, Bataille F, Pauer A, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK: Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays. J Clin Pathol; 2006 Jul;59(7):699-705
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
  • AIM: To investigate whether protein expression or cellular localisation of P-cadherin is associated with clinicopathological characteristics in benign and malignant melanocytic skin tumours.
  • In general, P-cadherin expression was significantly reduced in malignant melanomas (p<0.001) and melanoma metastases (p<0.001), compared with benign nevi.
  • [MeSH-minor] Aged. Cell Membrane / metabolism. Cytoplasm / metabolism. Disease Progression. Epidemiologic Methods. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Prognosis. Protein Array Analysis / methods. Recurrence

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:207-35 [14570569.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):683-90 [12875987.001]
  • [Cites] J Pathol. 2004 Aug;203(4):933-9 [15258996.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5270-82 [15289333.001]
  • [Cites] J Cell Biol. 1991 Apr;113(1):173-85 [2007622.001]
  • [Cites] Cell. 1991 Jul 12;66(1):107-19 [2070412.001]
  • [Cites] J Cell Biol. 1994 Oct;127(1):247-56 [7929567.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2470-5 [7758001.001]
  • [Cites] Genomics. 1995 Mar 20;26(2):281-9 [7601454.001]
  • [Cites] J Pathol. 1996 Nov;180(3):283-9 [8958806.001]
  • [Cites] J Pathol. 1998 Dec;186(4):350-5 [10209482.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1473-82 [15735123.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1835-41 [15756007.001]
  • [Cites] Exp Cell Res. 2005 May 1;305(2):418-26 [15817166.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4415-29 [15958626.001]
  • [Cites] Ann Plast Surg. 2005 Sep;55(3):316-20 [16106174.001]
  • [Cites] Mol Pathol. 1999 Jun;52(3):151-7 [10621837.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24661-6 [11323412.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Oct;44(1):1-15 [12398996.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):459-65 [12496470.001]
  • [Cites] Melanoma Res. 2003 Apr;13(2):147-52 [12690297.001]
  • [Cites] Expert Rev Mol Diagn. 2003 May;3(3):303-30 [12779006.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):193-203 [14695333.001]
  • (PMID = 16565225.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1860409
  •  go-up   go-down


40. Cerroni L, Barnhill R, Elder D, Gottlieb G, Heenan P, Kutzner H, LeBoit PE, Mihm M Jr, Rosai J, Kerl H: Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol; 2010 Mar;34(3):314-26
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008.
  • Several reports demonstrated the difficulties and lack of agreement in the histopathologic diagnosis of particular melanocytic tumors (atypical Spitz tumors, atypical blue nevi, deep penetrating nevi).
  • These lesions are often referred to as "melanocytic tumors of uncertain malignant potential" (MELTUMP).
  • We studied a large number of such tumors to find out whether repeatable histopathologic criteria for distinction of benign from malignant cases exist.
  • The major outcome of this study of a series of "MELTUMPs" suggests as a preliminary observation that these lesions as a group exist and that they may be biologically different from conventional melanoma and benign melanocytic nevi.
  • The terminology remains highly controversial, reflecting the uncertainty in classification and interpretation of these atypical melanocytic tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Inflammation / pathology. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Mitosis. Neoplasm Invasiveness. Neoplasm Staging. Terminology as Topic. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118771.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  •  go-up   go-down


41. Gambichler T, Rotterdam S, Radkowski K, Altmeyer P, Kreuter A: Differential expression of microtubule-associated protein 2 in melanocytic skin lesions. Am J Clin Pathol; 2009 May;131(5):710-4
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
  • We aimed to study the expression of microtubule-associated protein 2 (MAP-2) in different types of melanocytic skin lesions.
  • Paraffin-embedded sections of 42 benign nevi (BN), 22 dysplastic nevi (DN), 45 superficial spreading melanomas (SSMs), and 15 subcutaneous melanoma metastases were immunohistologically assessed using the monoclonal mouse MAP-2ab antibody (Zytomed, Berlin, Germany).
  • We observed that MAP-2 is differentially expressed during the development and progression of benign and malignant melanocytic skin lesions.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Disease Progression. Female. Humans. Immunohistochemistry. Male. Melanocytes / metabolism. Melanocytes / pathology. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369632.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MAP2 protein, human; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


42. Wild PJ, Meyer S, Bataille F, Woenckhaus M, Ameres M, Vogt T, Landthaler M, Pauer A, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK: Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors. Arch Dermatol; 2006 Apr;142(4):471-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors.
  • BACKGROUND: Using tissue microarrays, we investigated whether methylthioadenosine phosphorylase (MTAP) protein expression is associated with clinicopathologic variables in benign and malignant melanocytic skin tumors.
  • Expression was significantly reduced in primary malignant melanomas and in melanoma metastases compared with benign nevi (P<.001 for both).
  • [MeSH-major] Melanoma / metabolism. Neoplasm Recurrence, Local / metabolism. Purine-Nucleoside Phosphorylase / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Case-Control Studies. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Germany / epidemiology. Humans. Immunohistochemistry. Interferons / therapeutic use. Male. Microarray Analysis. Middle Aged. Neoplasm Metastasis. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618867.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9008-11-1 / Interferons; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 2.4.2.28 / 5'-methylthioadenosine phosphorylase
  •  go-up   go-down


43. Miracco C, Cevenini G, Franchi A, Luzi P, Cosci E, Mourmouras V, Monciatti I, Mannucci S, Biagioli M, Toscano M, Moretti D, Lio R, Massi D: Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions. Hum Pathol; 2010 Apr;41(4):503-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
  • This study was designed to assess the expression of Beclin 1 and LC3 in cutaneous melanocytic lesions, in which they have not yet been investigated.
  • In 149 lesions, including benign nevi, dysplastic nevi, radial growth phase melanomas, vertical growth phase melanomas, and melanoma metastases, proteins were evaluated by immunohistochemistry, and, in representative cases of benign nevi, vertical growth phase melanomas and melanoma metastases were evaluated by Western blotting.
  • The percentage of cases with high cytoplasmic expression of beclin 1 from 100% in benign nevi declined to 86.4% in dysplastic nevi, 54.5% in radial growth phase melanomas, 54.3% in vertical growth phase melanomas, and 26.7% in melanoma metastases.
  • In a multivariate analysis, messenger RNAs for both genes discriminated between nonmalignant (benign and dysplastic nevi) and malignant (radial, vertical growth phase melanomas, and melanoma metastases) lesions.
  • Our results, therefore, indicate that beclin 1 and LC3 II autophagic gene expression is altered also in melanocytic neoplasms.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Autophagy. Humans. Immunohistochemistry. Melanocytes / metabolism. Melanocytes / pathology. Middle Aged. Neoplasm Metastasis. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Skin / metabolism. Skin / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc.
  • (PMID = 20004946.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BECN1 protein, human; 0 / Membrane Proteins; 0 / Microtubule-Associated Proteins; 0 / light chain 3, human
  •  go-up   go-down


44. Scope A, Tabanelli M, Busam KJ, Rabinovitz H, Braun RP, Marghoob AA: Dispelling the myth of the "benign hair sign" for melanoma. J Am Acad Dermatol; 2007 Mar;56(3):413-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dispelling the myth of the "benign hair sign" for melanoma.
  • The vast majority of melanocytic lesions with hair, such as congenital melanocytic nevi, are benign.
  • However, there is a notion that the presence of one or more hairs in a melanocytic lesion is confirmatory for the benign nature of the lesion.
  • To dispel this notion, we present 3 examples of melanocytic lesions that showed terminal hairs on clinical and dermoscopic evaluation, but in which the final diagnosis was invasive melanoma.
  • [MeSH-major] Hair / pathology. Melanoma / pathology. Neoplasm Invasiveness. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156892.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Moretti D, Del Bello B, Cosci E, Biagioli M, Miracco C, Maellaro E: Novel variants of muscle calpain 3 identified in human melanoma cells: cisplatin-induced changes in vitro and differential expression in melanocytic lesions. Carcinogenesis; 2009 Jun;30(6):960-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel variants of muscle calpain 3 identified in human melanoma cells: cisplatin-induced changes in vitro and differential expression in melanocytic lesions.
  • Our recent demonstration of a proapoptotic role of ubiquitous calpains in drug-induced apoptosis of melanoma cells prompted us to investigate the expression of calpain 3 in human melanoma cell lines undergoing apoptosis and in melanocytic lesions.
  • Interestingly, among melanocytic lesions, the expression of these novel variants is significantly downregulated, compared with benign nevi, in the most aggressive ones, i.e. in vertical growth phase melanoma and, even more, in metastatic melanoma cells, characterized by invasiveness properties and usually highly resistant to apoptosis.
  • [MeSH-minor] Alternative Splicing. Apoptosis. Biopsy. Cell Line, Tumor. Cell Nucleolus / metabolism. Cytoplasm / metabolism. Dipeptides / pharmacology. Dysplastic Nevus Syndrome / metabolism. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Metastasis. RNA, Messenger / metabolism


46. Zaballos P, Llambrich A, Puig S, Malvehy J: Dermoscopy is useful for the recognition of benign-malignant compound tumours. Br J Dermatol; 2005 Sep;153(3):653-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopy is useful for the recognition of benign-malignant compound tumours.
  • In cases where a malignant neoplasm exists in association with a benign lesion it is important to make an accurate diagnosis in order to treat the lesions correctly.
  • We describe the dermoscopic characteristics of various collision or compound tumours that were composed of benign and malignant neoplasms: two cases of seborrhoeic keratosis associated with basal cell carcinoma, two cases of melanocytic naevus and basal cell carcinoma and one case of dermatofibroma associated with basal cell carcinoma.
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Histiocytoma, Benign Fibrous / diagnosis. Humans. Keratosis, Seborrheic / diagnosis. Male. Middle Aged. Nevus, Pigmented / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16120160.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 14
  •  go-up   go-down


47. Forsea AM, Carstea EM, Ghervase L, Giurcaneanu C, Pavelescu G: Clinical application of optical coherence tomography for the imaging of non-melanocytic cutaneous tumors: a pilot multi-modal study. J Med Life; 2010 Oct-Dec;3(4):381-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical application of optical coherence tomography for the imaging of non-melanocytic cutaneous tumors: a pilot multi-modal study.
  • OBJECTIVE: We aimed to investigate the utility of OCT for the diagnosis of non-melanocytic, non-pigmented cutaneous tumors.
  • [MeSH-minor] Bowen's Disease / pathology. Early Diagnosis. Epidermal Cyst / pathology. Histiocytoma, Benign Fibrous / pathology. Humans. Neoplasm Invasiveness. Pilot Projects. Prospective Studies. Sarcoma, Kaposi / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skin Res Technol. 2008 Feb;14(1):89-92 [18211606.001]
  • [Cites] Lasers Surg Med. 2007 Oct;39(9):687-95 [17960754.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):629-37 [17610989.001]
  • [Cites] Skin Res Technol. 2007 May;13(2):119-32 [17374052.001]
  • [Cites] J Dermatol Sci. 2007 Mar;45(3):167-73 [17215110.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):044011 [16965168.001]
  • [Cites] J Am Acad Dermatol. 1997 Dec;37(6):958-63 [9418764.001]
  • [Cites] Nat Med. 1995 Sep;1(9):970-2 [7585229.001]
  • [Cites] J Biomed Opt. 2004 Mar-Apr;9(2):292-8 [15065894.001]
  • [Cites] Skin Res Technol. 2001 Feb;7(1):1-9 [11301634.001]
  • [Cites] J Pathol. 2000 Jun;191(2):115-9 [10861568.001]
  • [Cites] Dermatology. 2008;217(1):14-20 [18309240.001]
  • [Cites] Arch Dermatol Res. 2010 Mar;302(2):105-11 [19894055.001]
  • [Cites] Opt Express. 2009 Oct 26;17(22):19486-500 [19997169.001]
  • [Cites] Semin Cutan Med Surg. 2009 Sep;28(3):196-202 [19782944.001]
  • [Cites] Dermatol Surg. 2009 Jun;35(6):965-72 [19397661.001]
  • [Cites] Skin Res Technol. 2008 Aug;14(3):364-9 [19159385.001]
  • [ErratumIn] J Med Life. 2011 Jan-Mar;4(1):7 p following 123
  • (PMID = 21254735.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Other-IDs] NLM/ PMC3019059
  •  go-up   go-down


48. Fredricks JR, Bejarano PA: Primary malignant melanoma of the esophagus with separate foci of melanoma in situ and atypical melanocytic hyperplasia in a patient positive for human immunodeficiency virus: a case report and review of the literature. Arch Pathol Lab Med; 2008 Oct;132(10):1675-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the esophagus with separate foci of melanoma in situ and atypical melanocytic hyperplasia in a patient positive for human immunodeficiency virus: a case report and review of the literature.
  • Primary malignant melanoma of the esophagus (PMME) is a rare neoplasm.
  • The primary nature of esophageal melanoma has been questioned in the past because most reported cases have not been able to demonstrate local tumorigenesis or evolution of the malignancy from a preceding benign lesion or cell.
  • We report a case of PMME with separate foci of melanoma in situ and atypical melanocytic hyperplasia in a patient with human immunodeficiency virus infection.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834229.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


49. Zembowicz A, Knoepp SM, Bei T, Stergiopoulos S, Eng C, Mihm MC, Stratakis CA: Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions. Am J Surg Pathol; 2007 Nov;31(11):1764-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
  • Pigmented epithelioid melanocytoma (PEM) is a recently described entity comprising most cases previously described as "animal-type melanoma" and epithelioid blue nevus (EBN) occurring in patients with the multiple neoplasia syndrome Carney complex (CNC).
  • In this study, we investigated whether PEM and EBN are related at the molecular level, and whether changes in the PRKAR1A gene status and the expression of the R1alpha protein may be involved in the pathogenesis of PEM and other melanocytic lesions.
  • Histologic analysis of hematoxylin and eosin-stained sections and immunohistochemistry (IHC) with R1alpha antibody were performed on 34 sporadic PEMs, 8 CNC-associated PEMs from patients with known PRKAR1A mutations, 297 benign and malignant melanocytic tumors (127 conventional sections of 10 compound nevi, 10 Spitz nevi, 5 deep-penetrating nevi, 5 blue nevi, 6 cellular blue nevi, 2 malignant blue nevi, 3 lentigo maligna, and 86 melanomas of various types); in addition, 170 tissue microarray sections consisting of 35 benign nevi, 60 primary melanomas, and 75 metastatic melanomas, and 5 equine dermal melanomas, were examined.
  • IHC showed that R1alpha was expressed in all but one core from tissue microarrays (169/170), and in all 127 melanocytic lesions evaluated in conventional sections.
  • The results support the concept that PEM is a distinct melanocytic tumor occurring in a sporadic setting and in the context of CNC.
  • [MeSH-minor] Animals. Chromosomes, Human, Pair 17. Diagnosis, Differential. Down-Regulation. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Horses. Humans. Immunohistochemistry. Loss of Heterozygosity. Mutation. Neoplasm Invasiveness. Neoplasm Metastasis. Terminology as Topic. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059235.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / PRKAR1A protein, human
  •  go-up   go-down


50. Piedra MP, Scheithauer BW, Driscoll CL, Link MJ: Primary melanocytic tumor of the cerebellopontine angle mimicking a vestibular schwannoma: case report. Neurosurgery; 2006 Jul;59(1):E206; discussion E206
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary melanocytic tumor of the cerebellopontine angle mimicking a vestibular schwannoma: case report.
  • OBJECTIVE: The majority of tumors of the cerebellopontine angle (CPA) are benign.
  • INTERVENTION: A translabyrinthine approach revealed a pigmented, vascular neoplasm encasing vessels and cranial nerves of the left CPA.

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16823290.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Parfitt JR, Bella AJ, Izawa JI, Wehrli BM: Malignant neoplasm of perivascular epithelioid cells of the liver. Arch Pathol Lab Med; 2006 Aug;130(8):1219-22
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant neoplasm of perivascular epithelioid cells of the liver.
  • Neoplasms of perivascular epithelioid cells (PEComas) have in common the coexpression of muscle and melanocytic immunohistochemical markers.
  • While most reported PEComas have behaved in a benign fashion, malignant PEComas have occasionally been documented.
  • We present a case of hepatic PEComa with benign histologic features, which nonetheless presented with metastases to multiple sites nearly 9 years later.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879028.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Basak PY, Hofmann-Wellenhof R: [Early melanoma as opposed to a benign nevus, nevus-associated melanoma, or halo nevus with regression?]. Hautarzt; 2010 Sep;61(9):785-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early melanoma as opposed to a benign nevus, nevus-associated melanoma, or halo nevus with regression?].
  • A 43-year-old woman, in whom a melanoma associated with a melanocytic nevus had been removed 2 years previously, came for a follow-up examination presenting with two light brown to medium brown maculae measuring approximately 7x5 mm with a flat papular center.
  • [MeSH-major] Melanoma / pathology. Neoplasm Recurrence, Local / pathology. Nevus / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Dermatol. 2003 Sep;28(5):476-80 [12950330.001]
  • [Cites] Br J Dermatol. 2004 Jan;150(1):64-71 [14746618.001]
  • [Cites] Arch Dermatol. 2006 Dec;142(12):1627-32 [17178990.001]
  • [Cites] Arch Dermatol. 2010 Apr;146(4):459-60 [20404249.001]
  • (PMID = 20814777.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Gondivkar SM, Indurkar A, Degwekar S, Bhowate R: Primary oral malignant melanoma--a case report and review of the literature. Quintessence Int; 2009 Jan;40(1):41-6
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant melanoma is a neoplasm of melanocytic origin that arises from a benign melanocytic lesion or de novo from melanocytes within otherwise normal mucosa or skin.
  • [MeSH-minor] Adult. Humans. Male. Maxilla / surgery. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19159022.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


54. Pouryazdanparast P, Newman M, Mafee M, Haghighat Z, Guitart J, Gerami P: Distinguishing epithelioid blue nevus from blue nevus-like cutaneous melanoma metastasis using fluorescence in situ hybridization. Am J Surg Pathol; 2009 Sep;33(9):1396-400
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These lesions may clinically and histologically simulate benign blue nevi.
  • The histologic changes may be indistinguishable from conventional blue nevi or epithelioid blue nevi (EBN), a benign dermal-based melanocytic neoplasm with epithelioid morphology and heavily pigmented cytoplasm.
  • Distinguishing BN-like cutaneous melanoma metastasis from benign conventional or EBN is important for staging and treatment.
  • FISH is an important diagnostic adjunct for melanocytic neoplasms.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Young Adult


55. Sangüeza M, Zelger B: Melanoma simulating atypical fibroxanthoma. Am J Dermatopathol; 2007 Dec;29(6):551-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present series describes 4 cases of such melanomas in 3 patients whose exact diagnosis was (markedly) delayed due to unusual clinicopathological presentations including negative immunohistochemistry for melanocytic markers (S100 protein, MelanA/MART1, HMB45).
  • [MeSH-major] Histiocytoma, Benign Fibrous / diagnosis. Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Diagnostic Errors / prevention & control. Fatal Outcome. Female. Humans. Male. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032950.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


56. De Panfilis G, Ferrari D, Santoro S, Ricci R, Lombardi M, Pedrazzi G, Pepe C, Cortelazzi C, Santini M: Cytoplasmic beta-catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: potential implications for melanoma tumorigenesis? Br J Dermatol; 2009 Mar;160(3):600-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate the role played in vivo by beta-catenin in melanoma tumorigenesis, we compared the cytoplasmic detection of beta-catenin in benign melanocytic cells vs. malignant melanoma cells presumably generated from these benign melanocytic cells.
  • For this purpose, melanocytic naevi occurring in association with melanoma, which were suggested to be melanoma precursors, were compared with their associated melanoma for beta-catenin cytoplasmic immunoreactivity.
  • METHODS: Fifty-seven consecutive cases of primary cutaneous melanoma were considered, and 15 of them were found to be associated with a melanocytic naevus portion.
  • The naevus portion showed features of acquired melanocytic naevus (total 12 cases: five dysplastic, seven intradermal) or congenital growth pattern naevus (total three cases: one superficial, two deep).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytoplasm / metabolism. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183173.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / beta Catenin
  •  go-up   go-down


57. Matsuo Y, Kamitani T: Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma. PLoS One; 2010;5(5):e10481
MedlinePlus Health Information. consumer health - Parkinson's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the expression of alpha-synuclein in human melanoma tissues, we immunostained sections of melanoma, nevus, non-melanocytic cutaneous carcinoma, and normal skin. alpha-Synuclein was positively detected in 86% of the primary and 85% of the metastatic melanoma sections, as well as in 89% of nevus sections.
  • However, alpha-synuclein was undetectable in non-melanocytic cutaneous carcinoma and normal skin.
  • CONCLUSIONS/SIGNIFICANCE: The Parkinson's disease-related protein, alpha-synuclein, is expressed in both malignant and benign melanocytic lesions, such as melanomas and nevi.
  • Although alpha-synuclein cannot be used to distinguish between malignant and benign melanocytic skin lesions, it might be a useful biomarker for the diagnosis of metastatic melanoma.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Cell Line, Tumor. Female. Humans. MART-1 Antigen. Male. Melanins / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Nevus / metabolism. Nevus / pathology. Pigmentation. Retinoblastoma / metabolism. Retinoblastoma / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Mar;54(3):196-200 [11253130.001]
  • [Cites] Neurology. 2009 Oct 20;73(16):1286-91 [19841380.001]
  • [Cites] J Neurosci. 2002 Apr 15;22(8):3090-9 [11943812.001]
  • [Cites] Nat Rev Neurosci. 2002 Jul;3(7):531-41 [12094209.001]
  • [Cites] Traffic. 2002 Sep;3(9):678-93 [12191019.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):217-23 [14991540.001]
  • [Cites] J Immunother. 1998 Jan;21(1):27-31 [9456433.001]
  • [Cites] Cancer. 1999 Feb 25;87(1):37-42 [10096358.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):617-27 [10440689.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):201-5 [15583688.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] J Cell Sci. 2005 Aug 1;118(Pt 15):3523-30 [16030137.001]
  • [Cites] Epidemiology. 2006 Sep;17(5):582-7 [16837822.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):786-97 [17878918.001]
  • [Cites] Orphanet J Rare Dis. 2007;2:43 [17980020.001]
  • [Cites] Nat Clin Pract Oncol. 2009 Feb;6(2):105-17 [19107110.001]
  • [Cites] Virchows Arch. 2009 May;454(5):505-11 [19352698.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1792(7):616-24 [18955133.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1039-46 [11474288.001]
  • (PMID = 20463956.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG024497
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanins; 0 / Neoplasm Proteins; 0 / alpha-Synuclein
  • [Other-IDs] NLM/ PMC2864738
  •  go-up   go-down


58. Yang YP, Zhu YL, Wu WP, Wang ZM, Zhang JM: [Perivascular epithelioid cell tumor of uterus: report of 5 cases and literature review]. Zhonghua Bing Li Xue Za Zhi; 2007 May;36(5):302-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemically, the tumor cells demonstrated positive staining for melanocytic markers (HMB45 and/or Melan-A), desmin and smooth muscle actin.
  • Positivity for melanocytic markers (especially HMB45) plays an important role in the diagnosis of this tumor.
  • In general, the tumor is categorized as benign, with uncertain malignant potential and malignant.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Neoplasm Proteins / metabolism. Perivascular Epithelioid Cell Neoplasms / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706136.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Desmin; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  • [Number-of-references] 24
  •  go-up   go-down


59. Cassarino DS, Miller WJ, Auerbach A, Yang A, Sherry R, Duray PH: The effects of gp100 and tyrosinase peptide vaccinations on nevi in melanoma patients. J Cutan Pathol; 2006 May;33(5):335-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Immunohistochemistry showed no differences in staining due to vaccination in either the immunologic or melanocytic markers.
  • Nevi were studied in order to assess the effects on benign melanocytes.
  • No significant changes in lymphocytes, langerhans cells, expression of MHC antigens, or melanocytic markers were found.
  • The increase in p53 and bcl-2 raises the possibility that vaccination with melanocytic antigens stimulates a response in benign melanocytes.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. HLA Antigens / drug effects. Humans. Immunohistochemistry. Ki-67 Antigen / drug effects. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Proto-Oncogene Proteins c-bcl-2 / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. T-Lymphocytes / drug effects. T-Lymphocytes / immunology. Tumor Suppressor Protein p53 / drug effects. Tumor Suppressor Protein p53 / metabolism. gp100 Melanoma Antigen

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640539.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cancer Vaccines; 0 / HLA Antigens; 0 / Ki-67 Antigen; 0 / Membrane Glycoproteins; 0 / PMEL protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / gp100 Melanoma Antigen; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


60. Saornil MA, Becerra E, Méndez MC, Blanco G: [Conjunctival tumors]. Arch Soc Esp Oftalmol; 2009 Jan;84(1):7-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They comprise a large variety of conditions, from benign lesions such as nevus or papilloma, to malignant lesions such as epidermoid carcinoma or melanoma which may threaten visual function and the life of the patient.
  • They can arise from any cellular component, but the most frequent are of epithelial and melanocytic origin.
  • [MeSH-minor] Carcinoma / pathology. Carcinoma / surgery. Conjunctival Diseases / pathology. Conjunctival Diseases / surgery. Eye Enucleation. Eye Evisceration. Hematologic Neoplasms / pathology. Hematologic Neoplasms / surgery. Humans. Melanoma / pathology. Melanoma / surgery. Neoplasm Invasiveness. Nevus / pathology. Nevus / surgery. Papilloma / pathology. Papilloma / surgery. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Sarcoma / pathology. Sarcoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173134.001).
  • [ISSN] 1989-7286
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 47
  •  go-up   go-down


61. Carlson JA, Ross JS, Slominski AJ: New techniques in dermatopathology that help to diagnose and prognosticate melanoma. Clin Dermatol; 2009 Jan-Feb;27(1):75-102
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Not all melanocytic tumors can be confidently classified as melanoma or benign nevus by histology, however.
  • Recent advances in molecular techniques and bioinformatics mandate testing and use of novel methods for the detection, diagnosis, and classification of melanocytic tumors that can accurately predict tumor behavior and help in selecting the most optimal and individualized therapy.
  • [MeSH-minor] Cytogenetic Analysis. Dermatology / methods. Humans. Immunohistochemistry. Molecular Diagnostic Techniques. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095155.001).
  • [ISSN] 1879-1131
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 288
  •  go-up   go-down


62. Finn LS, Argenyi ZB: Congenital panfollicular nevus: report of a new entity. J Cutan Pathol; 2005 Jan;32(1):59-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The various forms of non-melanocytic nevi (hamartomas) are usually encountered in pediatric patients, and nevus sebaceous of Jadassohn is the most common to have undifferentiated pilosebaceous units.
  • We report a unique congenital follicular nevus that fails to meet the criteria of any previously described follicular neoplasm, despite the plethora of alternatives.
  • This benign lesion of abortive hair follicles was unassociated with any established genodermatous syndrome or other adnexal neoplasm.


63. Cash SH, Dever TT, Hyde P, Lee JB: Epidermolysis bullosa nevus: an exception to the clinical and dermoscopic criteria for melanoma. Arch Dermatol; 2007 Sep;143(9):1164-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Large acquired melanocytic nevi that occur in patients with epidermolysis bullosa (EB), referred to as EB nevi, may pose a diagnostic challenge because of their clinical and dermoscopic resemblance to melanoma.
  • These unconventional melanocytic nevi have been encountered in all categories of hereditary EB, most of them in childhood.
  • Although some of the reported cases have an alarming clinical appearance that is indistinguishable from melanoma, long-term follow-up has confirmed the benign nature of these rarely encountered melanocytic lesions.
  • Histopathologically, a pattern of persistent melanocytic neoplasm was observed.
  • CONCLUSION: Epidermolysis bullosa nevi are dynamic melanocytic lesions that may simulate melanoma.


64. Grunwald MH, Gat A, Amichai B: Pseudomelanoma after Solcoderm treatment. Melanoma Res; 2006 Oct;16(5):459-60
Hazardous Substances Data Bank. COPPER, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pseudomelanoma is a pathological entity describing the histological findings in cases of recurrences of a partially excised melanocytic nevus, resembling melanoma.
  • It has been used for the treatment of benign skin lesions.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Dermatologic Agents / adverse effects. Melanoma / chemically induced. Neoplasm Recurrence, Local / chemically induced. Nevus, Pigmented / diagnosis. Skin Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17013096.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Lactates; 0 / Nitrates; 789U1901C5 / Copper; Q40Q9N063P / Acetic Acid; Solcoderm
  •  go-up   go-down


65. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ: Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res; 2006 Aug 15;66(16):7833-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indeed, our group and others have elucidated the unique ability of embryonic microenvironments to normalize aggressive melanoma cells toward a more benign melanocytic phenotype.
  • [MeSH-minor] Cell Differentiation. Cell Division. Humans. Incidence. Neoplasm Invasiveness. Phenotype

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912153.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 59702
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


66. Knight CS, Cerfolio RJ, Winokur TS: Angiomyolipoma of the anterior mediastinum. Ann Diagn Pathol; 2008 Aug;12(4):293-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiomyolipoma is a benign tumor composed of varying proportions of smooth muscle cells, blood vessels, and adipose tissue that most commonly occurs in the kidney.
  • Immunohistochemical stains revealed positivity for smooth muscle actin and HMB-45, revealing the expression of smooth muscle and melanocytic markers characteristic of angiomyolipoma and other lesions in the PEComa family.
  • [MeSH-minor] Actins / metabolism. Antigens, Neoplasm / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Melanoma-Specific Antigens. Middle Aged. Muscle, Smooth / pathology. Neoplasm Proteins / metabolism. Thymoma / pathology. Thymus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620999.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


67. Mizobuchi T, Masahiro N, Iwai N, Kohno H, Okada N, Nakada S: Clear cell tumor of the lung: surgical and immunohistochemical findings. Gen Thorac Cardiovasc Surg; 2010 May;58(5):243-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry revealed tumor cells positive for vimentin and melanocytic markers (HMB-45 and melan-A) and negative for epithelial membrane antigen and cytokeratin.
  • With the absence of clinical findings in both kidneys, the tumor was diagnosed as a benign CCTL.
  • [MeSH-minor] Aged. Antigens, Neoplasm / analysis. Female. Humans. Incidental Findings. MART-1 Antigen. Melanoma-Specific Antigens. Neoplasm Proteins / analysis. Tomography, X-Ray Computed. Treatment Outcome. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449716.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / Vimentin
  •  go-up   go-down


68. Walsh SN, Sangüeza OP: PEComas: a review with emphasis on cutaneous lesions. Semin Diagn Pathol; 2009 Aug;26(3):123-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Characteristically, the cells express both melanocytic (usually HMB45) and myogenic (typically actin) markers.
  • Most reported cutaneous PEComas follow a benign course, however, a malignant case has been reported.
  • [MeSH-minor] Actins / metabolism. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Female. Humans. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2016 Feb;38(2):165-6 [26825164.001]
  • (PMID = 20043511.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  • [Number-of-references] 65
  •  go-up   go-down


69. Kmetz EC, Sanders H, Fisher G, Lang PG, Maize JC Sr: The role of observation in the management of atypical nevi. South Med J; 2009 Jan;102(1):45-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some believe that atypical nevi are common variants of benign melanocytic nevi while others believe they are lesions intermediate between benign melanocytic nevi and melanoma.
  • [MeSH-major] Dysplastic Nevus Syndrome / surgery. Neoplasm Recurrence, Local / prevention & control. Observation. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077745.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Nguyen TT, Gorman B, Shields D, Goodman Z: Malignant hepatic angiomyolipoma: report of a case and review of literature. Am J Surg Pathol; 2008 May;32(5):793-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatic angiomyolipoma, a constituent of the group of tumors showing differentiation resembling perivascular epithelioid cells, is primarily appreciated in its benign form.
  • These tumors also possess similar immunohistochemical profiles, including positivity for melanocytic (HMB-45) and smooth muscle (smooth muscle actin) markers.
  • We will discuss the features that aid in distinguishing between benign and malignant HAML, and their similarities.
  • In summary, the common features of both benign and malignant HAML include the following: the 3 basic histologic components of AML, expression of melanocytic and smooth muscle markers, invasion into adjacent normal parenchyma, and cytologic atypia.
  • [MeSH-minor] Adipocytes / chemistry. Adipocytes / pathology. Adult. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Fatal Outcome. Female. Hepatectomy. Humans. Melanoma-Specific Antigens. Neoplasm Metastasis. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391749.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


71. Fu YJ, Morota N, Nakagawa A, Takahashi H, Kakita A: Neurocutaneous melanosis: surgical pathological features of an apparently hamartomatous lesion in the amygdala. J Neurosurg Pediatr; 2010 Jul;6(1):82-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurocutaneous melanosis (NCM) is a rare, congenital phakomatosis characterized by the presence of congenital melanocytic nevi and a benign or malignant pigmented cell tumor of the leptomeninges of the CNS.
  • In the temporal neocortex adjacent to the amygdaloid melanocytic lesion, cortical dysplasia with cortical laminar disorganization was evident.
  • Based on the histopathological features, the parenchymal lesion appeared to be hamartomatous in nature rather than a neoplasm, involving aberrant migration of melanocytes into the developing neuroepithelial tissue.


72. Schittek B, Psenner K, Sauer B, Meier F, Iftner T, Garbe C: The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer; 2007 May 15;120(10):2110-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In previous studies we identified the transcription/translation factor Y-box-binding protein (YB-1) as a gene that is upregulated in primary melanoma and melanoma metastases when compared to benign melanocytic nevi.
  • To analyze whether YB-1 expression correlates with melanoma progression in vitro and in vivo, we performed expression analysis on melanoma cell lines representing different stages of melanoma progression and on tissues of melanocytic nevi, primary melanoma and melanoma metastases.
  • Our data indicate that compared to benign melanocytes YB-1 expression is increased in melanoma cells in vitro and in vivo and that YB-1 is translocated into the nucleus in invasive and metastatic melanoma cells.
  • [MeSH-minor] Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Cell Nucleus / metabolism. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Invasiveness. Transfection. Up-Regulation


73. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, Bosenberg M: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet; 2009 May;41(5):544-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upon induction of BRaf(V600E) expression, mice developed benign melanocytic hyperplasias that failed to progress to melanoma over 15-20 months.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.Cg-Braf<tm1Mmcm> Pten<tm1Hwu> Tg(Tyr-cre/ERT2)13Bos/BosJ (subscription/membership/fee required).
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.129P2(Cg)-Braf<tm1Mmcm>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3396-403 [15060160.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2366s-2370s [16609060.001]
  • [Cites] Hum Pathol. 2006 May;37(5):520-7 [16647948.001]
  • [Cites] Genesis. 2006 May;44(5):262-7 [16676322.001]
  • [Cites] Science. 2006 Jul 28;313(5786):521-2 [16809487.001]
  • [Cites] Genes Dev. 2006 Aug 15;20(16):2149-82 [16912270.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):581-6 [16880785.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5277-87 [17000660.001]
  • [Cites] Genes Dev. 2007 Feb 15;21(4):379-84 [17299132.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1576-83 [17332304.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4738-48 [17260012.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):664-73 [18245465.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6 [18287029.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1800-4 [10766161.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2046-51 [18421059.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5760-8 [18632629.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):1851-63 [18606717.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):22128-35 [18508762.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3 [18510589.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Oct;21(5):534-44 [18715233.001]
  • [Cites] Adv Cancer Res. 2000;79:123-56 [10818679.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):139-40 [10835623.001]
  • [Cites] Mol Med Today. 2000 Oct;6(10):408-10 [11006531.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):446-54 [11904317.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Invest Dermatol. 2002 Oct;119(4):783-92 [12406321.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):117-30 [12620407.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):25-40 [12781369.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3053-62 [12789280.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3063-9 [12789281.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):559-70 [12894244.001]
  • [Cites] Genesis. 2003 Nov;37(3):131-8 [14595836.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):337-41 [15009714.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E59 [14691534.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2338-42 [15059882.001]
  • [Cites] J Biol Chem. 1991 Jan 15;266(2):1147-56 [1898730.001]
  • [Cites] Cell. 1994 Jul 15;78(1):35-43 [7518356.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5598-611 [9271435.001]
  • [Cites] Genes Dev. 1998 Oct 1;12(19):2997-3007 [9765202.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3467-81 [9832500.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85 [15520807.001]
  • [Cites] Nat Struct Mol Biol. 2004 Dec;11(12):1192-7 [15543157.001]
  • [Cites] Curr Biol. 2005 Feb 8;15(3):249-54 [15694309.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jan;24(1):165-83 [15785879.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):745-9 [15951821.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Front Biosci. 2006;11:733-42 [16146765.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2376s-2383s [16609062.001]
  • (PMID = 19282848.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] ENG
  • [Grant] None / None / / R01 CA112054-04; United States / NCI NIH HHS / CA / CA089124-01; United States / NCI NIH HHS / CA / U01 CA084313; United States / NCI NIH HHS / CA / CA 89124; United States / NCI NIH HHS / CA / R01 CA112054-03; United States / NCI NIH HHS / CA / R01 CA108972; United States / NCI NIH HHS / CA / CA 112054; United States / NCI NIH HHS / CA / K08 CA089124-03; United States / NCI NIH HHS / CA / R01 CA112054-05; United States / NCI NIH HHS / CA / R01 CA112054-04; United States / NCI NIH HHS / CA / CA089124-05; United States / NCI NIH HHS / CA / K08 CA089124-02; United States / NCI NIH HHS / CA / CA 84313; United States / NCI NIH HHS / CA / CA089124-03; United States / NCI NIH HHS / CA / K08 CA089124-01; None / None / / R01 CA112054-02; United States / NCI NIH HHS / CA / K08 CA089124-04; United States / NCI NIH HHS / CA / CA089124-02; United States / NCI NIH HHS / CA / CA089124-04; United States / NCI NIH HHS / CA / CA 108972; None / None / / R01 CA112054-01A1; None / None / / R01 CA112054-05; United States / NCI NIH HHS / CA / R01 CA112054-02; United States / NCI NIH HHS / CA / K08 CA089124; United States / NCI NIH HHS / CA / K08 CA089124-05; United States / NCI NIH HHS / CA / R01 CA112054; United States / NCI NIH HHS / CA / R01 CA112054-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multiprotein Complexes; 0 / Proteins; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS103221; NLM/ PMC2705918
  •  go-up   go-down


74. Mineo JF, P-Ruchoux MM, Pasquier D, Rigolle H, Assaker R: [Primitive malignant melanoma arising in a spinal nerve root. A case report]. Neurochirurgie; 2006 Jun;52(2-3 Pt 1):133-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry showed melanin, HMB-45 and S100 positivity, but reticulin was negative (that eliminates malignant melanocytic schwannoma).
  • The most common tumor with root enlargement and bony scalloping is the benign schwannoma.
  • Despite the above described radiological features, MRI characteristics (hyperintensity when images are T1-weighted) suggest a melanocytic tumor, a tumor with a high adipose component or an intratumoral bleeding.
  • According to the index of proliferation, a primitive central melanocytic lesion can be a meningeal melanocytoma (considered as benign) or a primitive malignant melanoma.
  • The histological features of malignant lesion with benign clinical features lead to interrogation upon the actual pathologic classification.
  • [MeSH-minor] Adult. Antigens, Neoplasm. Cell Proliferation. Fatal Outcome. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Melanins / metabolism. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. Neurologic Examination. S100 Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840974.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanins; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


75. Sanki A, Li W, Colman M, Karim RZ, Thompson JF, Scolyer RA: Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology; 2007 Dec;39(6):551-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To determine if the cyclin dependent kinase inhibitors (CDKIs) p16 and p27 show reduced expression in the progression from benign to malignant melanocytic tumours, and to correlate these findings with patient prognosis.
  • METHODS: Ninety-two melanocytic tumours were assessed for immunohistochemical expression of p16 and p27.
  • Positive expression of nuclear p16 was evident in 73.7% of benign naevi, 28.2% of primary melanomas and 14.7% of metastatic melanomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Disease Progression. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027257.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


76. Jakobiec FA, Bhat P, Colby KA: Immunohistochemical studies of conjunctival nevi and melanomas. Arch Ophthalmol; 2010 Feb;128(2):174-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the role of immunohistochemical methods in the diagnosis of benign and malignant conjunctival melanocytic proliferations.
  • CONCLUSIONS: S-100 and MART-1 were not useful in separating benign from malignant lesions.
  • Immunostaining for HMB-45 and Ki-67 are valuable adjuncts to careful histopathologic evaluation in assessing benign and malignant conjunctival melanocytic tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Conjunctival Neoplasms / diagnosis. Melanoma / diagnosis. Neoplasm Proteins / analysis. Nevus, Pigmented / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD45 / analysis. Antigens, Neoplasm / analysis. Child. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / analysis. MART-1 Antigen. Male. Melanoma-Specific Antigens. Middle Aged. Retrospective Studies. S100 Proteins / analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20142539.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


77. Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H: IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol; 2008 Apr;21(4):431-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IMP-3 expression in melanocytic neoplasms has not been investigated.
  • Fifty-six melanocytic neoplasms from 48 subjects were immunohistochemically studied using a monoclonal antibody against L523S/IMP-3.
  • None of the benign nevi and dysplastic nevi expressed IMP-3.
  • Our study demonstrates that IMP-3 is expressed in malignant melanoma but not in benign nevi, even when dysplastic features are present; IMP-3 is expressed in a significantly higher proportion of melanomas than Spitz nevi; and IMP-3 is expressed in metastatic melanomas significantly more than in thin melanomas.
  • Additionally, IMP-3 may have diagnostic utility in distinguishing melanoma from benign nevic cells, dysplastic nevi, and Spitz nevi.
  • [MeSH-major] Biomarkers, Tumor / analysis. Melanoma / metabolism. Melanoma / pathology. Neoplasm Proteins / metabolism. RNA-Binding Proteins / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204432.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


78. Tanaka M: Dermoscopy. J Dermatol; 2006 Aug;33(8):513-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second, some introduction on the difference of dermoscopic pictures between benign and malignant neoplasm is given.
  • Basically, benign lesions tend to show symmetrical dermoscopic structures and colors, whereas malignant lesions have a tendency to present irregular and atypical dermoscopic structures.
  • Acral melanocytic lesions have site-specific dermoscopic patterns, namely parallel furrow pattern or parallel ridge pattern.
  • These parallel patterns are due to different distribution of benign and malignant melanocytes.
  • Benign melanocytes (nevus cells) are mainly found on the tips of crista profunda limitans and supply melanin granules to the furrows of stratum corneum, making a parallel furrow pattern.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923131.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 0
  •  go-up   go-down


79. Busam KJ: Cutaneous desmoplastic melanoma. Adv Anat Pathol; 2005 Mar;12(2):92-102
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It may simulate histologically sclerosing melanocytic nevi as well as various benign and malignant nonmelanocytic lesions.
  • There is significant morphologic variability among tumors classified as DM.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Fibrosis. Humans. Neoplasm Recurrence, Local. Nevus, Pigmented / diagnosis. S100 Proteins / analysis. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15731577.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  • [Number-of-references] 56
  •  go-up   go-down


80. Strzelczyk JM, Durczynski A, Szymanski D, Jablkowski M, Dworniak D, Sporny S: Primary perivascular epithelioid cell tumor (PEComa) of the liver: report of a case. Surg Today; 2009;39(10):916-21
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PEComa is very rare mesenchymal neoplasm which is formed by perivascular epithelioid cells and is characterized by dual melanocytic and myoid differentiation.
  • A final histopathologic examination revealed a benign epithelioid tumor with a solid growth pattern, abundant vascularity, and frequently dilated vascular channels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19784736.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 24
  •  go-up   go-down


81. Michailidou C, Jones M, Walker P, Kamarashev J, Kelly A, Hurlstone AF: Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model. Dis Model Mech; 2009 Jul-Aug;2(7-8):399-411
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Deregulated Ras signalling is implicated in most human neoplasia, exemplified by melanoma.
  • Whereas Raf activation occurs almost ubiquitously in benign and malignant melanocytic neoplasms, implying an involvement in tumour initiation, phosphoinositide 3-kinase (PI3K) activation occurs predominantly in malignant neoplasms, implying an involvement in malignant progression.
  • Misexpression of effector-domain mutants of V12RAS, or of various downstream effectors, confirmed a selective role for the Raf-Mek-Erk pathway in initiating neoplasia, but highlighted the requirement for additional Ras effector pathways for malignancy.
  • [MeSH-minor] Animals. Cell Differentiation. Cell Line. Disease Models, Animal. Disease Progression. Humans. Mice. Mutation. Neoplasm Invasiveness. Protein Isoforms. Signal Transduction. Skin Neoplasms / metabolism. Zebrafish

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470611.001).
  • [ISSN] 1754-8411
  • [Journal-full-title] Disease models & mechanisms
  • [ISO-abbreviation] Dis Model Mech
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / raf Kinases
  •  go-up   go-down


82. Zyrek-Betts J, Micale M, Lineen A, Chaudhuri PK, Keil S, Xue J, Thomas JE: Malignant blue nevus with lymph node metastases. J Cutan Pathol; 2008 Jul;35(7):651-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We present a patient with metastatic malignant blue nevus and studies on the histopathologic, immunohistochemical, and molecular features of the neoplasm.
  • Molecular loss of heterozygosity analysis showed different allelic patterns at the hOGG-1 locus between the melanoma and control skin specimens with a varying heterozygous allelic pattern in both the benign and malignant blue nevus.
  • Further study is needed to determine if hOGG-1 mutation or c-kit upregulation play a role in the pathogenesis of dendritic melanocytic lesions (either benign or malignant).

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976211.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Ki-67 Antigen; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human
  •  go-up   go-down


83. Roesch A, Wittschier S, Becker B, Landthaler M, Vogt T: Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi. Mod Pathol; 2006 Oct;19(10):1378-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The deep penetrating nevus is a rare variant of benign melanocytic nevus with histologic features mimicking vertical growth phase, nodular malignant melanoma.
  • Dipeptidyl peptidase IV/CD26 was analyzed as a marker affecting both proliferation and invasion of malignant melanocytic tumors.
  • [MeSH-minor] Antibodies, Antinuclear / analysis. Antibodies, Monoclonal / analysis. Cell Proliferation. Diagnosis, Differential. Humans. Ki-67 Antigen / analysis. Matrix Metalloproteinases / metabolism. Neoplasm Invasiveness. Retinoblastoma Protein / analysis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16829852.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / MIB-1 antibody; 0 / Retinoblastoma Protein; EC 3.4.14.5 / DPP4 protein, human; EC 3.4.14.5 / Dipeptidyl Peptidase 4; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


84. Wadasadawala T, Trivedi S, Gupta T, Epari S, Jalali R: The diagnostic dilemma of primary central nervous system melanoma. J Clin Neurosci; 2010 Aug;17(8):1014-1017
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CNS can be affected by a spectrum of melanocytic lesions ranging from diffuse neurocutaneous melanosis, to a focal and benign neoplasm (melanocytoma), and to an overtly malignant tumor (melanoma).
  • Primary melanocytic lesions involving the CNS are typically concentrated in the perimedullary and high cervical region.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627582.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


85. McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD: Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol; 2007 Aug;34(8):597-600
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to determine the pattern of EZH2 expression in benign and malignant melanocytic tumors to see if EZH2 might play a role in melanoma pathogenesis and progression.
  • RESULTS: We observed an incremental increase in EZH2 expression from benign nevi to melanoma: scores of 1.18 and 1.08 for ordinary and dysplastic nevi, 1.7 and 1.78 for Spitz nevi and in situ melanoma, and 1.9 and 3.0 for invasive and metastatic melanoma, respectively.
  • EZH2 expression for metastatic melanoma was significantly higher compared with invasive and in situ melanoma and benign nevi (p < or = 0.01).
  • CONCLUSIONS: EZH2 protein levels increase incrementally from benign nevi to melanoma, which suggests that EZH2 may play a role in the pathogenesis and progression of melanoma.
  • [MeSH-minor] Disease Progression. Humans. Immunohistochemistry. Neoplasm Invasiveness. Polycomb Repressive Complex 2. Polycomb-Group Proteins. Repressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640228.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA 090876; United States / NCI NIH HHS / CA / R01 CA 107469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Polycomb-Group Proteins; 0 / Repressor Proteins; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2
  •  go-up   go-down


86. Ghazali N, Cascarini L, Norris P, Barrett AW, Lavery KM: Perivascular epithelioid cell tumor (PEComa) of the cheek. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jul;110(1):e26-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PEComa is a rare, recently described, family of tumors with diverse clinicopathologic expression and which express melanocytic and muscle markers.
  • Other possible diagnoses considered included benign mesenchymal tumors of smooth muscle or neural origin.
  • [MeSH-minor] Actins / analysis. Adult. Antigens, Neoplasm / analysis. Arterioles / pathology. Diagnosis, Differential. Epithelioid Cells / pathology. Female. Follow-Up Studies. Humans. MART-1 Antigen. Muscle, Smooth, Vascular / pathology. Neoplasm Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20610292.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


87. Nakatsura T, Nishimura Y: Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs; 2005;19(2):71-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of GPC3 mRNA and protein was evident in tumor cells from >80% of patients with melanoma and melanocytic nevus, which is a common benign lesion.
  • GPC3 protein was detected in sera from 40% (36/91) of melanoma patients, but not in sera from those with large congenital melanocytic nevus, or from healthy donors.
  • [MeSH-major] Antigens, Neoplasm. Carcinoma, Hepatocellular / diagnosis. Heparan Sulfate Proteoglycans. Melanoma / diagnosis. Molecular Diagnostic Techniques / trends

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807627.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Glypicans; 0 / Heparan Sulfate Proteoglycans
  • [Number-of-references] 59
  •  go-up   go-down


88. Sondak VK, Messina JL: Current status of biomarkers for melanoma metastasis. IDrugs; 2006 Sep;9(9):627-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In many cases, biomarkers are initially developed based on unequivocal index cases, such as clearly benign or clearly malignant melanocytic lesions, but then fail as predictive tools when applied to the more difficult cases that arise in clinical practice; such cases occupy a 'gray' zone that is filled with uncertainty and lacks an established 'gold standard' against which a biomarker prediction can be validated.
  • [MeSH-major] Biomarkers. Melanoma / diagnosis. Neoplasm Metastasis / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952070.001).
  • [ISSN] 1369-7056
  • [Journal-full-title] IDrugs : the investigational drugs journal
  • [ISO-abbreviation] IDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 11
  •  go-up   go-down


89. Abrahamsen HN, Sorensen BS, Nexo E, Hamilton-Dutoit SJ, Larsen J, Steiniche T: Pathologic assessment of melanoma sentinel nodes: a role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA. Clin Cancer Res; 2005 Feb 15;11(4):1425-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Molecular analysis of melanoma sentinel nodes (SN) is sensitive, but poorly specific because metastases cannot be distinguished from benign nevus inclusions (BNI).
  • Median MART-1 and tyrosinase mRNA levels in SNs were significantly different in patients with metastasis compared with patients with BNIs (P < 0.05) and patients without melanocytic lesions (P < 0.001).
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / genetics. MART-1 Antigen. Male. Middle Aged. Monophenol Monooxygenase / genetics. Neoplasm Proteins / genetics. Predictive Value of Tests. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746042.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


90. MacKie RM, Hauschild A, Eggermont AM: Epidemiology of invasive cutaneous melanoma. Ann Oncol; 2009 Aug;20 Suppl 6:vi1-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phenotypic markers of high-risk subjects include high counts of benign melanocytic naevi.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2007 Jun;156(6):1350-2 [17535234.001]
  • [Cites] Eur J Dermatol. 2007 Sep-Oct;17(5):428-34 [17673388.001]
  • [Cites] Australas J Dermatol. 2007 Nov;48(4):208-16 [17956477.001]
  • [Cites] Melanoma Res. 2007 Dec;17(6):349-53 [17992116.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(17):2580-9 [17950596.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):583-9 [17974555.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2753-60 [18366057.001]
  • [Cites] Eur J Cancer. 2008 Jul;44(10):1345-89 [18280139.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):838-40 [18488026.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):886-91 [18488027.001]
  • [Cites] Lancet. 1999 Dec 11;354(9195):2029-31 [10636367.001]
  • [Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):457-62 [11291086.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2000 Nov;14(6):470-2 [11444268.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):765-73 [11500805.001]
  • [Cites] Br J Dermatol. 2001 Nov;145(5):784-8 [11736902.001]
  • [Cites] Lancet Oncol. 2002 Mar;3(3):159-65 [11902502.001]
  • [Cites] J Med Screen. 2002;9(1):33-7 [11943795.001]
  • [Cites] BMJ. 2002 Sep 14;325(7364):567 [12228131.001]
  • [Cites] J Am Acad Dermatol. 2003 Jan;48(1):34-41 [12522368.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 4;95(11):806-12 [12783935.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):770-2 [14970851.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):683-9 [15097950.001]
  • [Cites] Br J Dermatol. 2004 Oct;151(4):868-72 [15491428.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2067-78 [15372475.001]
  • [Cites] Int J Cancer. 1980 Mar 15;25(3):317-23 [7390655.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Apr 12;292(6526):987-9 [3083979.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Jun 14;292(6535):1555-9 [3087514.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):1-4 [2365492.001]
  • [Cites] BMJ. 1992 Apr 18;304(6833):1012-5 [1586781.001]
  • [Cites] BMJ. 1996 May 4;312(7039):1125-8 [8620127.001]
  • [Cites] Arch Dermatol. 1998 Jan;134(1):103-4 [9449921.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):276-80 [9766557.001]
  • [Cites] Eur J Cancer. 2004 Nov;40(16):2355-66 [15519506.001]
  • [Cites] Br J Dermatol. 2005 Mar;152(3):481-8 [15787817.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):761-3 [15824139.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1241-4 [15894679.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1962-7 [16187269.001]
  • [Cites] Cancer Causes Control. 2006 Feb;17(1):11-9 [16411048.001]
  • [Cites] Ann Dermatol Venereol. 2005 Dec;132(12 Pt 1):975-82 [16446640.001]
  • [Cites] Br J Dermatol. 2006 Mar;154(3):472-7 [16445778.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1010-6 [16152577.001]
  • [Cites] Curr Opin Oncol. 2006 Mar;18(2):173-9 [16462187.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1116-22 [17131335.001]
  • [Cites] Am J Epidemiol. 2007 Mar 1;165(5):505-13 [17158470.001]
  • [Cites] J Dermatol Sci. 2007 Apr;46(1):61-4 [17223014.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1174-82 [17265520.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):991-7 [17507627.001]
  • [Cites] Br J Cancer. 2007 Jun 4;96(11):1772-7 [17533392.001]
  • (PMID = 19617292.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 53
  • [Other-IDs] NLM/ PMC2712590
  •  go-up   go-down


91. Deprez M, Uffer S: Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol; 2009 May;31(3):256-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eyelid tumors are the most common neoplasm in daily ophthalmology practice and encompass a wide variety of benign and malignant tumors.
  • Benign tumors largely predominated over malignant ones, representing 84% of cases in this series, and the 5 most frequent subtypes were squamous cell papilloma (26%), seborrheic keratosis (21%), melanocytic nevus (20%), hidrocystoma (8%), and xanthoma/xanthelasma (6%).

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384066.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


92. Roesch A, Becker B, Bentink S, Spang R, Vogl A, Hagen I, Landthaler M, Vogt T: Ataxia telangiectasia-mutated gene is a possible biomarker for discrimination of infiltrative deep penetrating nevi and metastatic vertical growth phase melanoma. Cancer Epidemiol Biomarkers Prev; 2007 Nov;16(11):2486-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The deep penetrating nevus (DPN) is a variant of benign melanocytic nevus with clinical and histologic features mimicking vertical growth phase, nodular malignant melanoma (NMM).
  • Beyond the clinical demand for precise diagnosis and diagnosis-adapted, preventive therapeutic strategies, the DPN represents a valuable natural model for melanocytic invasion without metastatic potential that per se deserves further investigations.
  • [MeSH-minor] Ataxia Telangiectasia Mutated Proteins. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis / methods

  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Ataxia Telangiectasia.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006941.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


93. Rothhammer T, Wild PJ, Meyer S, Bataille F, Pauer A, Klinkhammer-Schalke M, Hein R, Hofstaedter F, Bosserhoff AK: Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma. Cancer Biomark; 2007;3(2):111-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to investigate whether protein expression of bone morphogenetic protein 7 (BMP7) is associated with clinico-pathologic characteristics in benign and malignant melanocytic skin tumors.
  • In general, BMP7 expression was significantly induced in malignant melanomas (P< 0.001) and melanoma metastases (P< 0.001), compared to benign nevi.
  • [MeSH-minor] Bone Morphogenetic Protein 7. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522432.001).
  • [ISSN] 1574-0153
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BMP7 protein, human; 0 / Biomarkers, Tumor; 0 / Bone Morphogenetic Protein 7; 0 / Bone Morphogenetic Proteins; 0 / Transforming Growth Factor beta
  •  go-up   go-down


94. Massi D, Landriscina M, Piscazzi A, Cosci E, Kirov A, Paglierani M, Di Serio C, Mourmouras V, Fumagalli S, Biagioli M, Prudovsky I, Miracco C, Santucci M, Marchionni N, Tarantini F: S100A13 is a new angiogenic marker in human melanoma. Mod Pathol; 2010 Jun;23(6):804-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the involvement of S100A13 in human cutaneous melanoma, we analyzed a series of 87 cutaneous melanocytic lesions: 14 common acquired melanocytic nevi, 14 atypical, so-called 'dysplastic' nevi, 45 melanomas (17 radial growth phase and 28 vertical growth phase) and 14 melanoma metastases.
  • We found that S100A13 was expressed in melanocytic lesions; compared with benign nevi, S100A13 protein expression was significantly upregulated in melanomas (P=0.024), in which it correlated positively with the intensity of VEGF-A staining (P=0.041) and microvessel density (P=0.007).
  • In conclusion, S100A13 is expressed in melanocytic lesions when the angiogenic switch occurs and it may cooperate with VEGF-A in supporting the formation of new blood vessels, favoring the shift from radial to vertical tumor growth.
  • [MeSH-minor] Aged. Antigens, CD / analysis. Female. Fibroblast Growth Factor 1 / analysis. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. RNA, Messenger / analysis. Receptors, Cell Surface / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2000 Jun;34(3):185-94 [10838264.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6199-206 [19917835.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22544-52 [11410600.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):223-35 [11438469.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1826-31 [11919240.001]
  • [Cites] FASEB J. 2003 Jun;17(9):984-92 [12773481.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):990-7 [15133476.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] Reprod Domest Anim. 2004 Oct;39(5):321-7 [15367264.001]
  • [Cites] Semin Oncol. 1975 Jun;2(2):119-47 [1234372.001]
  • [Cites] Science. 1984 Aug 31;225(4665):932-5 [6382607.001]
  • [Cites] Am J Pathol. 1993 Jul;143(1):99-104 [7686347.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):6061-6 [8261423.001]
  • [Cites] Am J Pathol. 1994 Feb;144(2):329-36 [8311116.001]
  • [Cites] J Biol Chem. 1995 Dec 8;270(49):29039-42 [7493920.001]
  • [Cites] J Invest Dermatol. 1996 Feb;106(2):207-8 [8601716.001]
  • [Cites] Melanoma Res. 1996 Apr;6(2):133-7 [8791271.001]
  • [Cites] Melanoma Res. 1996 Jun;6(3):223-30 [8819125.001]
  • [Cites] J Cutan Pathol. 1997 Apr;24(4):212-8 [9138111.001]
  • [Cites] Surg Oncol Clin N Am. 1997 Jul;6(3):599-623 [9210357.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):464-9 [9291441.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1659-73 [9647657.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):70-4 [10030417.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):770-4 [10463478.001]
  • [Cites] Reprod Biol. 2005 Mar;5(1):51-67 [15821778.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1955-8 [15900299.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):4993-7 [15958538.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):87-101 [16165218.001]
  • [Cites] Biochem J. 2006 Jun 1;396(2):201-14 [16683912.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):251-9 [16773219.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6):555-65 [18083379.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):151-9 [18061437.001]
  • [Cites] Eur J Surg Oncol. 2008 Apr;34(4):357-64 [17566693.001]
  • [Cites] J Cell Biochem. 2008 Apr 1;103(5):1327-43 [17786931.001]
  • [Cites] J Cutan Pathol. 2008 May;35(5):433-44 [18399807.001]
  • [Cites] Neoplasma. 2008;55(4):273-9 [18505336.001]
  • [Cites] Cancer Lett. 2008 Aug 18;267(1):67-74 [18400376.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):21-30 [18660796.001]
  • [Cites] Ann Oncol. 2009 Aug;20 Suppl 6:vi8-13 [19617299.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1717-26 [11245488.001]
  • (PMID = 20208480.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL035627; United States / NHLBI NIH HHS / HL / R01 HL035627; United States / NHLBI NIH HHS / HL / R01 HL035627-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / S100 Proteins; 0 / S100A13 protein, human; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 104781-85-3 / Fibroblast Growth Factor 1
  • [Other-IDs] NLM/ NIHMS204422; NLM/ PMC2882157
  •  go-up   go-down


95. Fagundes-Pereyra WJ, de Sousa L, Carvalho GT, Pittella JE, de Sousa AA: Meningeal melanocytoma of the posterior fossa: case report and literature review. Surg Neurol; 2005 Mar;63(3):269-73; discussion 273-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologic examination showed a highly cellular melanocytic neoplasm with numerous dark pigments in the cytoplasm.
  • CONCLUSIONS: In conclusion, MMs are rare histologically benign tumors that can be cured by complete surgical resection alone, which should be the goal of the treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15734524.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 29
  •  go-up   go-down


96. Altamura D, Avramidis M, Menzies SW: Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch Dermatol; 2008 Apr;144(4):502-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine whether 6 weeks could replace 3 months for short-term sequential digital dermoscopy imaging (ST-SDDI) of suspicious melanocytic lesions and determine the proportion of melanomas missed.
  • For lesions remaining unchanged at 3 months, 99.2% (1118 of 1127 lesions) were shown to be benign as defined by an unremarkable further follow-up.
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Cell Transformation, Neoplastic / pathology. Dysplastic Nevus Syndrome / diagnosis. Dysplastic Nevus Syndrome / pathology. Follow-Up Studies. Humans. Hutchinson's Melanotic Freckle / diagnosis. Hutchinson's Melanotic Freckle / pathology. Neoplasm Invasiveness. Odds Ratio. Sensitivity and Specificity. Skin / pathology. Software Design

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2008 Apr;144(4):533-4 [18427049.001]
  • (PMID = 18427044.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW: Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol; 2005 Dec;29(12):1558-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PEComas, occasionally associated with the tuberous sclerosis complex, are defined by the presence of perivascular epithelioid cells that coexpress muscle and melanocytic markers.
  • We conclude that PEComas of soft tissue and gynecologic origin may be classified as "benign," "of uncertain malignant potential," or "malignant."
  • Small PEComas without any worrisome histologic features are most likely benign.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Mitosis. Neoplasm Metastasis. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Tumor Burden

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327428.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 56
  •  go-up   go-down


98. Mourmouras V, Falzarano SM, Malagnino V, Miracco C: Compound melanocytic nevus associated with dermatofibroma: an additional case. J Cutan Pathol; 2007 Sep;34(9):736-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compound melanocytic nevus associated with dermatofibroma: an additional case.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. MART-1 Antigen. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Dermatofibroma.
  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696924.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down






Advertisement